
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number 001-36569

LANTHEUS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State of incorporation)

331 Treble Cove Road, North Billerica, MA
(Address of principal executive offices)

35-2318913
(IRS Employer
Identification No.)

01862
(Zip Code)

(978) 671-8001
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act) Yes No

The registrant had 31,472,015 of common stock, \$0.01 par value per share, issued and outstanding as of November 4, 2015.

TABLE OF CONTENTS

| | <u>Page</u> |
|--|--------------------|
| <u>PART I. FINANCIAL INFORMATION</u> | |
| Item 1. | 1 |
| Financial Statements (Unaudited) | 1 |
| Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2015 and 2014 | 1 |
| Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2015 and 2014 | 2 |
| Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014 | 3 |
| Condensed Consolidated Statements of Stockholders' Deficit for the Nine Months Ended September 30, 2015 and the Year Ended December 31, 2014 | 4 |
| Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2015 and 2014 | 5 |
| Notes to Unaudited Condensed Consolidated Financial Statements | 6 |
| Item 2. | 20 |
| Management's Discussion and Analysis of Financial Condition and Results of Operations | 20 |
| Item 3. | 35 |
| Quantitative and Qualitative Disclosures About Market Risk | 35 |
| Item 4. | 37 |
| Controls and Procedures | 37 |
| <u>PART II. OTHER INFORMATION</u> | |
| Item 1. | 37 |
| Legal Proceedings | 37 |
| Item 1A. | 37 |
| Risk Factors | 37 |
| Item 2. | 39 |
| Unregistered Sales of Equity Securities and Use of Proceeds | 39 |
| Item 4 | 39 |
| Mine Safety Disclosures | 39 |
| Item 6. | 40 |
| Exhibits | 40 |
| Signatures | 41 |
| Exhibit Index | 42 |

PART I. FINANCIAL INFORMATION**Item 1. Financial Statements (Unaudited)****Lantheus Holdings, Inc. and subsidiaries****Condensed Consolidated Statements of Operations****(unaudited, in thousands, except share data)**

| | For the Three Months Ended September 30, | | For the Nine Months Ended September 30, | |
|--------------------------------------|---|------------|--|------------|
| | 2015 | 2014 | 2015 | 2014 |
| Revenues | \$ 74,123 | \$ 75,682 | \$ 222,260 | \$ 224,631 |
| Cost of goods sold | 40,418 | 44,044 | 120,119 | 131,873 |
| Gross profit | 33,705 | 31,638 | 102,141 | 92,758 |
| Operating expenses | | | | |
| Sales and marketing expenses | 8,633 | 8,327 | 26,934 | 27,227 |
| General and administrative expenses | 9,206 | 11,041 | 33,773 | 28,883 |
| Research and development expenses | 2,458 | 3,049 | 11,292 | 8,958 |
| Total operating expenses | 20,297 | 22,417 | 71,999 | 65,068 |
| Operating income | 13,408 | 9,221 | 30,142 | 27,690 |
| Interest expense, net | (7,100) | (10,585) | (31,599) | (31,704) |
| Loss on extinguishment of debt | — | — | (15,528) | — |
| Other income (expense), net | (183) | 441 | 234 | (148) |
| Income (loss) before income taxes | 6,125 | (923) | (16,751) | (4,162) |
| Provision (benefit) for income taxes | 739 | (56) | 1,911 | (374) |
| Net income (loss) | \$ 5,386 | \$ (867) | \$ (18,662) | \$ (3,788) |
| Net income (loss) per common share: | | | | |
| Basic and diluted | \$ 0.18 | \$ (0.05) | \$ (0.83) | \$ (0.21) |
| Common shares: | | | | |
| Basic | 30,359,516 | 18,080,968 | 22,443,257 | 18,080,496 |
| Diluted | 30,761,771 | 18,080,968 | 22,443,257 | 18,080,496 |

See notes to unaudited condensed consolidated financial statements.

Lantheus Holdings, Inc. and subsidiaries
Consolidated Statements of Comprehensive Income (Loss)
(unaudited, in thousands)

| | For the Three Months | | For the Nine Months | |
|-----------------------------------|-----------------------------|-------------------|----------------------------|------------------|
| | Ended September 30, | | Ended September 30, | |
| | 2015 | 2014 | 2015 | 2014 |
| Net income (loss) | \$ 5,386 | \$ (867) | \$(18,662) | \$(3,788) |
| Foreign currency translation | (443) | (671) | (817) | (339) |
| Total comprehensive income (loss) | <u>\$ 4,943</u> | <u>\$ (1,538)</u> | <u>\$(19,479)</u> | <u>\$(4,127)</u> |

See notes to unaudited condensed consolidated financial statements.

[Table of Contents](#)

Lantheus Holdings, Inc. and subsidiaries
Condensed Consolidated Balance Sheets
(unaudited, in thousands, except share data)

| | September 30, 2015 | December 31, 2014 |
|---|-----------------------|----------------------|
| Assets | | |
| Current assets | | |
| Cash and cash equivalents | \$ 21,922 | \$ 19,739 |
| Accounts receivable, net of allowance of \$334 and \$585 | 39,724 | 41,540 |
| Inventory | 16,579 | 15,582 |
| Other current assets | 5,210 | 4,374 |
| Total current assets | 83,435 | 81,235 |
| Property, plant and equipment, net | 92,393 | 96,014 |
| Capitalized software development costs, net | 1,981 | 2,421 |
| Intangibles, net | 22,489 | 27,191 |
| Goodwill | 15,714 | 15,714 |
| Other long-term assets | 20,120 | 20,578 |
| Total assets | <u>\$ 236,132</u> | <u>\$ 243,153</u> |
| Liabilities and Stockholders' Deficit | | |
| Current liabilities | | |
| Line of credit | \$ — | \$ 8,000 |
| Accounts payable | 10,700 | 15,665 |
| Accrued expenses and other liabilities | 19,968 | 24,863 |
| Current portion of long-term debt | 3,650 | — |
| Total current liabilities | 34,318 | 48,528 |
| Asset retirement obligation | 8,074 | 7,435 |
| Long-term debt, net | 350,367 | 392,863 |
| Other long-term liabilities | 33,518 | 33,597 |
| Total liabilities | 426,277 | 482,423 |
| Commitments and contingencies (See Note 15) | | |
| Stockholders' deficit | | |
| Preferred stock (\$0.01 par value, 25,000,000 shares authorized; no shares issued and outstanding) | — | — |
| Common stock (\$0.01 par value, 250,000,000 shares authorized; 30,364,501 and 18,080,944 shares issued; 30,364,501 and 18,075,907 shares outstanding) | 303 | 181 |
| Treasury stock (no shares and 5,037 shares, at cost) | — | (106) |
| Additional paid-in capital | 175,075 | 106,699 |
| Accumulated deficit | (363,076) | (344,414) |
| Accumulated other comprehensive loss | (2,447) | (1,630) |
| Total stockholders' deficit | (190,145) | (239,270) |
| Total liabilities and stockholders' deficit | <u>\$ 236,132</u> | <u>\$ 243,153</u> |

See notes to unaudited condensed consolidated financial statements.

Lantheus Holdings, Inc. and subsidiaries

Condensed Consolidated Statements of Stockholders' Deficit

(unaudited, in thousands, except share data)

| | Preferred Stock | | Common Stock | | Treasury Stock | | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Total Stockholders' Deficit |
|--|-----------------|--------|--------------|--------|----------------|--------|----------------------------|---------------------|--------------------------------------|-----------------------------|
| | Shares | Amount | Shares | Amount | Shares | Amount | | | | |
| Balance at January 1, 2014 | — | \$ — | 18,078,725 | \$ 181 | (5,037) | (106) | \$105,655 | \$ (340,853) | \$ (394) | \$ (235,517) |
| Net share option exercise | — | — | 2,219 | — | — | — | 13 | — | — | 13 |
| Net loss | — | — | — | — | — | — | — | (3,561) | — | (3,561) |
| Other comprehensive loss | — | — | — | — | — | — | — | — | (1,236) | (1,236) |
| Stock-based compensation | — | — | — | — | — | — | 1,031 | — | — | 1,031 |
| Balance at December 31, 2014 | — | — | 18,080,944 | 181 | (5,037) | (106) | 106,699 | (344,414) | (1,630) | (239,270) |
| Issuance of common stock from initial public offering, net of \$6,362 issuance costs | — | — | 12,256,577 | 122 | — | — | 67,055 | — | — | 67,177 |
| Treasury stock retired | — | — | — | — | 5,037 | 106 | (106) | — | — | — |
| Net loss | — | — | — | — | — | — | — | (18,662) | — | (18,662) |
| Other comprehensive loss | — | — | — | — | — | — | — | — | (817) | (817) |
| Issuance of common stock | — | — | 40,000 | — | — | — | — | — | — | — |
| Shares withheld to cover taxes | — | — | (13,020) | — | — | — | (97) | — | — | (97) |
| Stock-based compensation | — | — | — | — | — | — | 1,524 | — | — | 1,524 |
| Balance at September 30, 2015 | — | \$ — | 30,364,501 | \$ 303 | — | — | \$175,075 | \$ (363,076) | \$ (2,447) | \$ (190,145) |

See notes to unaudited condensed consolidated financial statements.

Lantheus Holdings, Inc. and subsidiaries
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)

| | For the Nine Months Ended September 30, | |
|---|--|------------------|
| | 2015 | 2014 |
| Cash flows from operating activities | | |
| Net loss | \$ (18,662) | \$ (3,788) |
| Adjustments to reconcile net loss to cash flow from operating activities | | |
| Depreciation and amortization | 16,648 | 14,808 |
| Provision for excess and obsolete inventory | 1,073 | 1,529 |
| Stock-based compensation | 1,524 | 782 |
| Deferred income taxes | (85) | (30) |
| Loss on extinguishment of debt | 15,528 | — |
| Write-off of deferred financing costs | — | 2,319 |
| Other | 2,598 | (72) |
| Increase (decrease) in cash from operating assets and liabilities | | |
| Accounts receivable | 790 | (2,383) |
| Inventory | (2,441) | 668 |
| Other current assets | (1,075) | (1,312) |
| Accounts payable | (2,765) | (2,971) |
| Accrued expenses and other liabilities | (3,997) | 5,915 |
| Cash provided by operating activities | <u>9,136</u> | <u>15,465</u> |
| Cash flows from investing activities | | |
| Capital expenditures | (8,419) | (5,303) |
| Proceeds from sale of property, plant and equipment | — | 227 |
| Redemption of certificate of deposit - restricted | — | 228 |
| Cash used in investing activities | <u>(8,419)</u> | <u>(4,848)</u> |
| Cash flows from financing activities | | |
| Proceeds from issuance of common stock in initial public offering | 73,539 | — |
| Initial public offering costs | (6,258) | — |
| Proceeds from issuance of common stock, other | — | 13 |
| Proceeds from issuance of long-term debt | 360,438 | — |
| Payments on long-term debt | (969) | (52) |
| Payments on senior notes | (400,000) | — |
| Payment for call premium on senior notes | (9,752) | — |
| Payments on line of credit | (8,000) | (5,500) |
| Proceeds from line of credit | — | 5,500 |
| Payments for offering costs | (563) | (1,758) |
| Payment for tax withholding related to net share settlement of equity awards | (97) | — |
| Deferred financing costs | (6,297) | (139) |
| Cash provided by (used in) financing activities | <u>2,041</u> | <u>(1,936)</u> |
| Effect of foreign exchange rate on cash | (575) | (132) |
| Increase in cash and cash equivalents | 2,183 | 8,549 |
| Cash and cash equivalents, beginning of period | 19,739 | 18,578 |
| Cash and cash equivalents, end of period | <u>\$ 21,922</u> | <u>\$ 27,127</u> |
| Supplemental disclosure of cash flow information | | |
| Interest paid | \$ 34,275 | \$ 19,692 |
| Income taxes paid, net | \$ 81 | \$ 375 |
| Noncash investing and financing activities | | |
| Property, plant and equipment included in accounts payable and accrued expenses and other liabilities | \$ 940 | \$ 1,488 |
| Initial public offering costs included in accrued expenses and other liabilities | \$ 104 | \$ 561 |

See notes to unaudited condensed consolidated financial statements.

Lantheus Holdings, Inc. and subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

Unless the context otherwise requires, references to the “Company” and “Lantheus” refer to Lantheus Holdings, Inc. and its direct and indirect subsidiaries, references to “Holdings” refer to Lantheus Holdings, Inc., and not to any of its subsidiaries, and references to “LMI” refer to Lantheus Medical Imaging, Inc., the direct subsidiary of Holdings. Solely for convenience, we refer to trademarks, service marks and trade names are referred to without the TM, SM and ® symbols. Those references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent permitted under applicable law, its rights to its trademarks, service marks and trade names.

1. Business Overview

Overview

Holdings, a Delaware corporation, is the parent company of LMI, also a Delaware corporation.

The Company develops, manufactures, sells and distributes innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company’s commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, technologists and sonographers working in a variety of clinical settings. The Company sells its products to radiopharmacies, hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations and, in certain circumstances, wholesalers. The Company sells its products globally and has operations in the United States, Puerto Rico, Canada and Australia and distribution relationships in Europe, Asia Pacific and Latin America.

The Company’s portfolio of 10 commercial products is diversified across a range of imaging modalities. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including the following:

- DEFINITY is the leading ultrasound contrast imaging agent used by cardiologists and sonographers during cardiac ultrasound, or echocardiography, exams based on revenue and usage. DEFINITY is an injectable agent that, in the United States, is indicated for use in patients with suboptimal echocardiograms to assist in the visualization of the left ventricle, the main pumping chamber of the heart. The use of DEFINITY in echocardiography allows physicians to significantly improve their assessment of the function of the left ventricle.
- TechnLite is a self-contained system, or generator, of technetium (Tc99m), a radioisotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents.
- Xenon Xe 133 Gas, or Xenon, is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow.
- Cardiolite is an injectable, technetium-labeled imaging agent, also known by its generic name sestamibi, used with Single Photon Emission Computed Tomography, or SPECT, technology in myocardial perfusion imaging, or MPI, procedures that assess blood flow distribution to the heart.
- Neurolite is an injectable, technetium-labeled imaging agent used with SPECT technology to identify the area within the brain where blood flow has been blocked or reduced due to stroke.

In the United States, the Company sells DEFINITY through its sales team that calls on healthcare providers in the echocardiography space, as well as group purchasing organizations and integrated delivery networks. The Company’s radiopharmaceutical products are primarily distributed through commercial radiopharmacies owned or controlled by third parties. In Canada, Puerto Rico and Australia, the Company owns seven radiopharmacies and sells its own radiopharmaceuticals, as well as others, directly to end users. In Europe, Asia Pacific and Latin America, the Company utilizes distributor relationships to market, sell and distribute its products.

Basis of Consolidation and Presentation

The financial statements have been prepared in United States dollars, in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The condensed consolidated financial statements include the accounts of Holdings and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

[Table of Contents](#)

In the opinion of the Company's management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company's financial statements for interim periods in accordance with U.S. GAAP. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The information included in this quarterly report should be read in conjunction with the Company's consolidated financial statements and the accompanying notes included in the Company's Prospectus dated June 24, 2015 and filed with the SEC on June 26, 2015, or the Prospectus. The Company's accounting policies are described in the "Notes to Consolidated Financial Statements" in the Prospectus and updated, as necessary, in this quarterly report. There were no changes to the Company's accounting policies since December 31, 2014 except that the Company has adopted a new accounting policy as discussed further below. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and nine months ended September 30, 2015 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

Recent Events

On June 25, 2015, in conjunction with its initial public offering, or IPO, the Company effected a corporate reorganization, whereby Lantheus MI Intermediate, Inc. (formerly the direct parent of LMI and the direct subsidiary of Holdings) was merged with and into Holdings, or the Merger.

On June 30, 2015, the Company completed an IPO of its common stock at a price to the public of \$6.00 per share. The Company's common stock is now traded on the NASDAQ Global Select Market (NASDAQ) under the symbol "LNTH". The Company issued and sold 12,256,577 shares of common stock in the IPO, including 1,423,243 shares that were offered and sold pursuant to the underwriters' exercise in full of its overallotment option. The IPO resulted in proceeds to the Company of approximately \$67.2 million, after deducting \$6.4 million in underwriting discounts, commissions and related expenses.

On June 30, 2015, the Company also entered into a \$365.0 million senior secured term loan facility, or the Term Facility. The net proceeds of the Term Facility, together with the net proceeds from the IPO and the cash use of \$10.9 million were used to repay in full the aggregate principal amount of LMI's \$400.0 million 9.750% Senior Notes due 2017, or the Notes, pay related premiums, interest and expenses and pay down the \$8.0 million of outstanding borrowings under LMI's \$50.0 million revolving credit facility, or the Revolving Facility.

The Company currently relies on Jubilant HollisterStier, or JHS, as its sole source manufacturer of DEFINITY, Neurolite and evacuation vials for TechneLite. The Company has additional ongoing technology transfer activities at JHS for its Cardiolite product supply, which is currently manufactured by a single manufacturer. In addition, the Company has ongoing technology transfer activities at Pharmalucence for the manufacture and supply of DEFINITY, and the Company believes it will file for U.S. Food and Drug Administration, or FDA, approval to manufacture DEFINITY at Pharmalucence in 2016.

The Company has historically been dependent on key customers and group purchasing organizations for the majority of the sales of its medical imaging products. The Company's ability to maintain and profitably renew these contracts and relationships with these key customers and group purchasing organizations is an important aspect of the Company's strategy. The Company's written supply agreements with a major customer relating to TechneLite, Xenon, Neurolite, Cardiolite and certain other products expired in accordance with contract terms on December 31, 2014. Extended discussions with this customer have not yet resulted in new written supply agreements. Consequently, the Company is currently accepting and fulfilling product orders with this customer on a purchase order basis.

Until the Company successfully becomes dual sourced for its principal products, the Company is vulnerable to future supply shortages. Disruption in the financial performance of the Company could also occur if it experiences significant adverse changes in customer mix, broad economic downturns, adverse industry or Company conditions or catastrophic external events. If the Company experiences one or more of these events in the future, it may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.

During 2013 and 2014, the Company has utilized its revolving line of credit as a source of liquidity from time to time. Borrowing capacity under the Revolving Facility is calculated by reference to a borrowing base consisting of a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves, or the Borrowing Base. If the Company is not successful in achieving its forecasted operating results, the Company's accounts receivable and inventory could be negatively affected, thus reducing the Borrowing Base and limiting the Company's borrowing capacity. As of September 30, 2015, the aggregate Borrowing Base was approximately \$46.2 million, which was reduced by the \$8.8 million unfunded Standby Letter of Credit and \$0.1

[Table of Contents](#)

million in accrued interest, resulting in a net Borrowing Base availability of approximately \$37.3 million. The Company's new Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the revolving line of credit may affect the Company's ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage. Accordingly, the Company may be limited in utilizing its net Borrowing Base availability as a source of liquidity.

Based on the Company's current operating plans, the Company believes its existing cash and cash equivalents, results of operations and availability under the Revolving Facility will be sufficient to continue to fund the Company's liquidity requirements for at least the next twelve months.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The more significant estimates reflected in the Company's condensed consolidated financial statements include certain judgments regarding revenue recognition, goodwill, tangible and intangible asset valuation, inventory valuation, asset retirement obligations, income tax liabilities and related indemnification receivable, deferred tax assets and liabilities, accrued expenses and stock-based compensation. Actual results could materially differ from those estimates or assumptions.

Stock Split

In conjunction with the Merger, the Company effected a 0.355872-for-1 reverse stock split for its common stock. Upon consummation of the Merger, the par value of the common stock changed from \$0.001 to \$0.01. Accordingly, all references to share and per share information in the condensed consolidated financial statements have been adjusted to reflect the stock split and new par value for all periods presented.

Debt Issuance Costs

In April 2015, the Financial Accounting Standards Board, or the FASB, issued ASU No. 2015-03, "*Interest—Imputation of Interest (Topic 835): Simplifying the Presentation of Debt Issuance Costs*," or ASU 2015-03. Under the new ASU, debt issuance costs related to a recognized debt liability will be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability. As a result, the Company's balance sheet will reflect a reclassification of unamortized debt issuance costs from other long-term assets to long-term debt, net. ASU 2015-03 is effective for interim and annual periods beginning after December 15, 2015, and early adoption is permitted. The Company has adopted this standard effective as of June 30, 2015 and applied the changes retrospectively to the prior periods presented. Adoption of this standard has resulted in the reclassification of \$6.4 million from other long-term assets to long-term debt, net on the balance sheet at December 31, 2014. Unamortized debt issuance costs of \$5.7 million are recorded as a reduction to long-term debt, net on the condensed consolidated balance sheets at September 30, 2015.

In August 2015, FASB issued ASU No. 2015-15 "*Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line of Credit Arrangements*," or ASU 2015-15. ASU 2015-15 indicates that the guidance in ASU 2015-03 did not address presentation or subsequent measurement of debt issuance costs related to line of credit arrangements. Given the absence of authoritative guidance within ASU 2015-03, the SEC staff has indicated that they would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the costs ratably over the term of the line of credit arrangement, regardless of whether there are any outstanding borrowings on the line of credit arrangement. The adoption of ASU 2015-15 did not have any effect on the Company's financial position or results of operations.

2. Summary of Significant Accounting Policies

Revenue Recognition

The Company recognizes revenue when evidence of an arrangement exists, title has passed, the risks and rewards of ownership have transferred to the customer, the selling price is fixed and determinable, and collectability is reasonably assured. For transactions for which revenue recognition criteria have not yet been met, the respective amounts are recorded as deferred revenue until such point in time the criteria are met and revenue can be recognized. Revenue is recognized net of reserves, which consist of allowances for returns and rebates.

Revenue arrangements with multiple elements are divided into separate units of accounting if certain criteria are met, including whether the delivered element has stand-alone value to the customer. The arrangement's consideration is then allocated to each

[Table of Contents](#)

separate unit of accounting based on the relative selling price of each deliverable. The estimated selling price of each deliverable is determined using the following hierarchy of values: (i) vendor-specific objective evidence of fair value; (ii) third-party evidence of selling price; and (iii) best estimate of selling price. The best estimate of selling price reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold by the Company on a stand-alone basis. The consideration allocated to each unit of accounting is then recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. Supply or service transactions may involve the charge of a nonrefundable initial fee with subsequent periodic payments for future products or services. The up-front fees, even if nonrefundable, are recognized as revenue as the products and/or services are delivered and performed over the term of the arrangement.

Inventory

Inventory costs associated with product that has not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use of the product and future economic benefits of the asset. If future commercial use of the product is not probable, then inventory costs associated with such product are expensed during the period the costs are incurred. For the nine months ended September 30, 2014, the Company expensed \$1.7 million of such product costs in cost of goods sold relating to NeuroLite that was manufactured by JHS. There was no significant product expensed for the nine months ended September 30, 2015. At September 30, 2015 and December 31, 2014, the Company had no capitalized inventories associated with product that did not have regulatory approval.

Goodwill

Goodwill is not amortized, but is instead tested for impairment at least annually and whenever events or circumstances indicate that it is more likely than not that it may be impaired. The Company has elected to perform the annual test for goodwill impairment as of October 31 of each year. There were no events as of September 30, 2015 and December 31, 2014 that triggered an interim impairment test of goodwill.

3. Fair Value of Financial Instruments

The tables below present information about the Company's assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2015 and December 31, 2014, and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points from active markets that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points for the asset or liability.

| | | Quoted prices in active markets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) |
|--|-----------------------------|--|--|--|
| September 30, 2015 (in thousands) | Total fair value | | | |
| Money market | \$ 1,722 | \$ 1,722 | \$ — | \$ — |
| Certificates of deposit—restricted | 77 | — | 77 | — |
| Total | \$ 1,799 | \$ 1,722 | \$ 77 | \$ — |
| | | | | |
| | | Quoted prices in active markets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) |
| December 31, 2014 (in thousands) | Total fair value | | | |
| Money market | \$ 2,737 | \$ 2,737 | \$ — | \$ — |
| Certificates of deposit—restricted | 89 | — | 89 | — |
| Total | \$ 2,826 | \$ 2,737 | \$ 89 | \$ — |

At both September 30, 2015 and December 31, 2014, the Company has a \$0.1 million certificate of deposit which is collateral for a long-term lease and is included in other long-term assets on the condensed consolidated balance sheet. Certificates of deposit are classified within Level 2 of the fair value hierarchy, as these are not traded on the open market.

At September 30, 2015, after giving effect to the closing of the IPO and the Term Facility, the repayment in full of the aggregate principal amount of \$400.0 million Notes together with related premiums, interest and expenses and the pay down of \$8.0 million of borrowings under the Revolving Facility, the Company had total cash and cash equivalents of \$21.9 million, which included

[Table of Contents](#)

approximately \$1.7 million of money market funds and \$20.2 million of cash on-hand. At December 31, 2014, the Company had total cash and cash equivalents of \$19.7 million, which included approximately \$2.7 million of money market funds and \$17.0 million of cash on-hand.

The estimated fair values of the Company's financial instruments, including its cash and cash equivalents, receivables, accounts payable and accrued expenses approximate the carrying values of these instruments due to their short term nature. The estimated fair value of the Company's Term Facility at September 30, 2015, approximates carrying value because the interest rate is subject to change with market interest rates. At December 31, 2014, the estimated fair value of the Senior Notes based on Level 2 inputs of recent market activity available to the Company was \$384.0 million compared to the face value of \$400.0 million.

4. Income Taxes

The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year in addition to discrete events which impact the interim period. The Company's effective tax rate differs from the U.S. statutory rate principally due to the rate impact of uncertain tax positions, valuation allowance changes and state taxes. Cumulative adjustments to the tax provision are recorded in the interim period in which a change in the estimated annual effective rate is determined. The Company's tax provision was \$0.7 million and \$1.9 million for the three and nine months ended September 30, 2015, respectively, compared to a tax benefit of \$0.1 million and \$0.4 million for the three and nine months ended September 30, 2014, respectively.

In connection with the Company's acquisition of the medical imaging business from Bristol-Myers Squibb, or BMS, in 2008, the Company obtained a tax indemnification agreement with BMS related to certain tax obligations arising prior to the acquisition of the Company, for which the Company has the primary legal obligation. The tax indemnification receivable is recognized within other long-term assets. The changes in the tax indemnification asset are recognized within other expense, net in the condensed consolidated statement of operations. In accordance with the Company's accounting policy, the change in the tax liability and penalties and interest associated with these obligations (net of any offsetting federal or state benefit) is recognized within the tax provision. Accordingly, as these reserves change, adjustments are included in the tax provision while the offsetting adjustment is included in other expense, net. Assuming that the receivable from BMS continues to be considered recoverable by the Company, there is no net effect on earnings related to these liabilities and no net cash outflows.

On March 13, 2014, New York State, BMS, the Company and a relator entered into a Stipulation and Settlement Agreement and other related agreements, or collectively the Settlement Documents, to resolve an investigation by the Office of the Attorney General of New York State, claims relating to certain New York State and New York City tax matters and related claims under the New York False Claims Act. The claims at issue arose during the period from January 1, 2002 through December 31, 2006, which predated the acquisition of the medical imaging business from BMS in January 2008 and are subject to the tax indemnification agreement described above. Pursuant to the Settlement Documents, BMS paid (on behalf of itself and the Company) \$6.3 million, and neither BMS nor the Company admitted any liability. The Company received a full release from New York State, New York City and the relator with respect to the claims at issue.

During the nine months ended September 30, 2015, BMS, on behalf of the Company, made payments totaling \$1.9 million to a number of states in connection with state income tax settlements. Within the next twelve months, unrecognized tax benefits of \$0.1 million may be recognized associated with transfer pricing due to the closing of the statute of limitations.

5. Inventory

The Company includes within current assets the amount of inventory that is estimated to be utilized within twelve months. Inventory that will be utilized after twelve months is classified within other long-term assets.

Inventory, classified in inventory or other long-term assets, consisted of the following:

| <u>(in thousands)</u> | <u>September 30,</u> <u>2015</u> | <u>December 31,</u> <u>2014</u> |
|------------------------|-------------------------------------|------------------------------------|
| Raw materials | \$ 7,172 | \$ 6,043 |
| Work in process | 4,129 | 1,788 |
| Finished goods | 5,278 | 7,751 |
| Inventory | 16,579 | 15,582 |
| Other long-term assets | 1,156 | 1,156 |
| Total | <u>\$ 17,735</u> | <u>\$ 16,738</u> |

[Table of Contents](#)

At both September 30, 2015 and December 31, 2014, inventories reported as other long-term assets included \$1.2 million of raw materials.

6. Property, Plant and Equipment, net

Property, plant and equipment consisted of the following:

| <u>(in thousands)</u> | <u>September 30,</u> <u>2015</u> | <u>December 31,</u> <u>2014</u> |
|------------------------------------|-------------------------------------|------------------------------------|
| Land | \$ 14,950 | \$ 14,950 |
| Buildings | 68,858 | 67,571 |
| Machinery, equipment and fixtures | 63,343 | 65,179 |
| Construction in progress | 12,775 | 9,746 |
| Accumulated depreciation | <u>(67,533)</u> | <u>(61,432)</u> |
| Property, plant and equipment, net | <u>\$ 92,393</u> | <u>\$ 96,014</u> |

For the three and nine months ended September 30, 2015, depreciation expense related to property, plant and equipment was \$1.9 million and \$9.6 million, respectively, as compared to \$2.2 million and \$6.5 million for the prior year comparative periods.

Included within machinery, equipment and fixtures are spare parts of approximately \$2.4 million and \$2.5 million at September 30, 2015 and December 31, 2014, respectively. Spare parts include replacement parts relating to plant and equipment and are either recognized as an expense when consumed or re-classified and capitalized as part of the related plant and equipment and depreciated over a time period not exceeding the useful life of the related asset.

Fixed assets dedicated to research and development, or R&D, activities, which were impacted by the March 2013 R&D strategic shift, have a carrying value of \$4.6 million as of September 30, 2015. The Company believes these fixed assets will be utilized for either internally funded ongoing R&D activities or R&D activities funded by a strategic partner. If the Company is not successful in finding a strategic partner and there are no alternative uses for these fixed assets, then they could be subject to impairment in the future.

Long-Lived Assets to Be Disposed of Other than by Sale

In November 2014, the Company announced its plans to decommission certain long-lived assets associated with its R&D operations in the United States. The Company expected the decommissioning to begin in the second half of 2015. As a result, the Company revised its estimates of the remaining useful lives of the affected long-lived assets to seven months.

During the second quarter of 2015, the Company halted its decommissioning plans until an indefinite date. As a result, the Company revised its estimates of the remaining useful lives of the affected long-lived assets back to its original remaining useful life effective April 1, 2015.

At September 30, 2015 and December 31, 2014, the net book value of these assets totaled \$4.4 million and \$7.4 million, respectively.

7. Asset Retirement Obligations

The Company considers the legal obligation to remediate its facilities upon a decommissioning of its radioactive related operations as an asset retirement obligation. The operations of the Company have radioactive production facilities at its North Billerica, Massachusetts and San Juan, Puerto Rico sites.

The Company is required to provide the U.S. Nuclear Regulatory Commission and Massachusetts Department of Public Health financial assurance demonstrating the Company's ability to fund the decommissioning of the North Billerica, Massachusetts production facility upon closure, although the Company does not intend to close the facility. The Company has provided this financial assurance in the form of a \$28.2 million surety bond, which itself is currently secured by an \$8.8 million unfunded Standby Letter of Credit provided to the third party issuer of the bond.

The fair value of a liability for asset retirement obligations is recognized in the period in which the liability is incurred. As of September 30, 2015, the liability is measured at the present value of the obligation expected to be incurred, of approximately \$26.0 million, and is adjusted in subsequent periods as accretion expense is recorded. The corresponding asset retirement costs are capitalized as part of the carrying value of the related long-lived assets and depreciated over the asset's useful life.

Table of Contents

The following is a reconciliation of the Company's asset retirement obligations for the nine months ended September 30, 2015:

| <u>(in thousands)</u> | |
|-------------------------------|----------------|
| Balance at January 1, 2015 | \$7,435 |
| Accretion expense | 639 |
| Balance at September 30, 2015 | <u>\$8,074</u> |

8. Intangibles, net

Intangibles, net consisted of the following:

| <u>(in thousands)</u> | <u>September 30, 2015</u> | | | <u>Amortization Method</u> |
|------------------------|---------------------------|---------------------------------|-----------------|----------------------------|
| | <u>Cost</u> | <u>Accumulated amortization</u> | <u>Net</u> | |
| Trademarks | \$ 13,540 | \$ 6,480 | \$ 7,060 | Straight-line |
| Customer relationships | 104,102 | 90,543 | 13,559 | Accelerated |
| Other patents | 42,780 | 40,910 | 1,870 | Straight-line |
| | <u>\$160,422</u> | <u>\$ 137,933</u> | <u>\$22,489</u> | |

| <u>(in thousands)</u> | <u>December 31, 2014</u> | | | <u>Amortization Method</u> |
|------------------------|--------------------------|---------------------------------|-----------------|----------------------------|
| | <u>Cost</u> | <u>Accumulated amortization</u> | <u>Net</u> | |
| Trademarks | \$ 13,540 | \$ 5,116 | \$ 8,424 | Straight-line |
| Customer relationships | 105,373 | 88,931 | 16,442 | Accelerated |
| Other patents | 42,780 | 40,455 | 2,325 | Straight-line |
| | <u>\$161,693</u> | <u>\$ 134,502</u> | <u>\$27,191</u> | |

For the three and nine months ended September 30, 2015, the Company recorded amortization expense for its intangible assets of \$1.5 million and \$4.5 million, respectively, as compared to \$1.9 million and \$5.7 million for the prior year comparative periods.

Expected future amortization expense related to the intangible assets is as follows:

| <u>(in thousands)</u> | |
|-----------------------|-----------------|
| Remainder of 2015 | \$ 1,467 |
| 2016 | 5,276 |
| 2017 | 3,473 |
| 2018 | 2,753 |
| 2019 | 1,886 |
| 2020 and thereafter | 7,634 |
| | <u>\$22,489</u> |

[Table of Contents](#)

9. Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities are comprised of the following:

| (in thousands) | September 30, 2015 | December 31, 2014 |
|--|-----------------------|----------------------|
| Compensation and benefits | \$ 11,152 | \$ 11,198 |
| Accrued interest | 94 | 4,994 |
| Accrued professional fees | 1,561 | 1,508 |
| Research and development services | 174 | 248 |
| Freight, distribution and operations | 3,199 | 3,069 |
| Marketing expense | 970 | 978 |
| Accrued rebates, discounts and chargebacks | 2,292 | 2,164 |
| Other | 526 | 704 |
| | <u>\$ 19,968</u> | <u>\$ 24,863</u> |

10. Financing Arrangements

Term Facility

On June 30, 2015, LMI entered into a new \$365.0 million seven-year Term Facility, which was issued net of a 1.25% discount of \$4.6 million. LMI has a right to request an increase of the Term Facility in an aggregate amount up to \$37.5 million plus additional amounts subject to certain leverage ratios. The net proceeds of the Term Facility, together with the net proceeds of the IPO and cash on hand, were used to refinance in full the aggregate principal amount of the Notes and pay related premiums, interest and expenses.

The term loans under the Term Facility bear interest, with pricing based from time to time at LMI's election at (i) LIBOR plus a spread of 6.00% (with a LIBOR rate floor of 1.00%) or (ii) the Base Rate (as defined in our Term Facility) plus a spread of 5.00%. Interest under term loans based on (i) the LIBOR rate is payable at the end of each interest period (as defined in our Term Facility) and (ii) the Base Rate is payable at the end of each quarter.

LMI is permitted to voluntarily prepay the Term Facility, in whole or in part, with a premium applicable for the first six months of the Term Facility in connection with a repricing transaction. LMI is required to make quarterly payments, which began on September 30, 2015, in an amount equal to a quarter of a percent (0.25%) per annum of the original principal amount of the Term Facility. The remaining unpaid principal amount of the Term Facility will be payable on the maturity date, or June 30, 2022.

The Term Facility will require LMI to prepay outstanding term loans, subject to certain exceptions, with:

- 100% of the net cash proceeds of all non-ordinary course sales or other dispositions of assets (including as a result of casualty or condemnation, subject to certain exceptions); the Company may reinvest or commit to reinvest certain of those proceeds in assets useful in our business within twelve months;
- 100% of the net cash proceeds from issuances or incurrence of debt, other than proceeds from debt permitted under the Term Facility and Revolving Facility;
- 50% (with two leverage-based stepdowns) of the Company's excess cash flow; and
- 50% of net payments from the Zurich insurance settlement (as defined therein).

The foregoing mandatory prepayments will be applied to the scheduled installments of principal of the Term Facility in direct order of maturity.

The Term Facility is guaranteed by the Company and Lantheus Real Estate, and obligations under the Term Facility are secured by substantially all the property and assets and all interests of the Company, LMI and Lantheus Real Estate.

Table of Contents

The Company's minimum payments of principal obligations under the Term Facility are as follows as of September 30, 2015:

| (in thousands) | |
|---------------------------------|------------------|
| Remainder of 2015 | \$ 913 |
| 2016 | 3,650 |
| 2017 | 3,650 |
| 2018 | 3,650 |
| 2019 | 3,650 |
| 2020 and thereafter | 348,575 |
| Total debt | 364,088 |
| Unamortized debt discount | (4,387) |
| Unamortized debt issuance costs | (5,684) |
| Total | 354,017 |
| Less current portion | (3,650) |
| Total long-term debt | <u>\$350,367</u> |

Term Facility Covenants

The Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Term Facility requires the Company to be in quarterly compliance, measured on a trailing four quarter basis. The financial covenants are displayed in the table below:

Term Facility Financial Covenants

| Period | Total Net Leverage Ratio |
|--------------------|---------------------------------|
| Q3 2015 to Q1 2016 | 6.25 to 1.00 |
| Q2 2016 to Q4 2016 | 6.00 to 1.00 |
| Q1 2017 to Q2 2017 | 5.50 to 1.00 |
| Thereafter | 5.00 to 1.00 |

The Term Facility contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Financing Costs

LMI incurred and capitalized approximately \$5.9 million in debt issuance costs, consisting primarily of underwriting fees and expenses and legal fees in connection with the issuance of the Term Facility. Unamortized debt issuance costs associated with the Term Facility are recorded as a reduction to long-term debt on the condensed consolidated balance sheets. Debt issuance costs are being amortized over the life of the Term Facility, as appropriate, using the effective interest method and are included in interest expense in the accompanying condensed consolidated statements of operations.

On June 30, 2015, LMI amended its existing Revolving Facility upon the closing of the Term Facility. The amendment extended the expiration date on the Revolving Facility and further modified certain definitions. In connection with the June 30, 2015 amendment, LMI incurred approximately \$0.4 million in fees and expenses, which is included in other current assets on the condensed consolidated balance sheets. These fees are being amortized over the remaining life of the Revolving Facility using the straight-line method and are included in interest expense in the accompanying consolidated statements of operations.

Senior Notes

LMI had \$400.0 million in aggregate principal amount of the Notes outstanding. The interest on the Notes was at a rate of 9.750% per year, payable on May 15 and November 15 of each year. The net proceeds of the Term Facility, together with the net proceeds of the IPO and cash on hand, were used to refinance in full the aggregate principal amount of the Notes and pay related premiums, interest and expenses. The Company satisfied and discharged its obligations under the Notes as of June 30, 2015. The notes and accrued interest were redeemed in full on July 30, 2015.

[Table of Contents](#)

The Company recorded a loss on extinguishment of debt totaling \$15.5 million, which included a redemption premium of \$9.7 million and a \$5.8 million write-off of unamortized debt issuance costs associated with the Senior Notes. On June 30, 2015, the Company also paid the accrued interest to the redemption date totaling \$3.3 million, which is included in interest expense for the nine months ending September 30, 2015 on the condensed consolidated statement of operations.

Revolving Line of Credit

At September 30, 2015, LMI has a Revolving Facility with an aggregate principal amount not to exceed \$50.0 million. The loans under the Revolving Facility bear interest subject to a pricing grid based on average historical excess availability, with pricing based from time to time at the election of LMI at (i) LIBOR plus a spread ranging from 2.00% or (ii) the Reference Rate (as defined in the agreement) plus 1.00%. The Revolving Facility also includes an unused line fee of 0.375% and expires on June 30, 2020.

As of September 30, 2015 and December 31, 2014, LMI has an unfunded Standby Letter of Credit for up to \$8.8 million. The unfunded Standby Letter of Credit requires an annual fee, payable quarterly, which is set at LIBOR plus a spread of 2.00% and expires on February 5, 2016, which will automatically renew for a one year period at each anniversary date, unless LMI elects not to renew in writing within 60 days prior to that expiration.

The Revolving Facility contains a number of affirmative, negative, reporting and financial covenants, as well as a financial covenant during trigger periods in the form of a consolidated fixed charge coverage ratio of not less than 1:00:1:00. Upon an event of default, the lender has the right to declare the loans and other obligations outstanding immediately due and payable and all commitments immediately terminated or reduced, and the lender may, after such events of default, require LMI to make deposits with respect to any outstanding letters of credit in an amount equal to 105% of the greatest amount for which such letter of credit may be drawn.

The Revolving Facility is guaranteed by Holdings and Lantheus Real Estate and is secured by a pledge of substantially all of the assets of each of the loan parties including accounts receivable, inventory and machinery and equipment. Borrowing capacity is determined by reference to a Borrowing Base, which is based on a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus any reserves. As of September 30, 2015, the aggregate Borrowing Base was approximately \$46.2 million, which was reduced by an outstanding \$8.8 million unfunded Standby Letter of Credit and \$0.1 million in accrued interest, resulting in a net Borrowing Base availability of approximately \$37.3 million.

11. Stockholders' Equity

As of September 30, 2015, the authorized capital stock of the Company consisted of 250,000,000 shares of common stock, par value \$0.01 per share, and 25,000,000 shares of preferred stock, par value \$0.01 per share. The common stockholders are entitled to one vote per share and will share equally on a per share basis in any dividend declared by the Board of Directors, subject to any preferential rights of the holders of any outstanding preferred stock.

12. Stock-Based Compensation

As of June 24, 2015, the Company adopted the 2015 Equity Incentive Plan, or the 2015 Plan.

The Company's employees are eligible to receive awards under the 2015 Plan. The 2015 Plan is administered by the Board of Directors and permits the granting of stock options, stock appreciation rights, or SARs, restricted stock, restricted stock units and dividend equivalent rights ("DERs") to employees, officers, directors and consultants of the Company. The Board of Directors may, at its sole discretion, grant DERs with respect to any award and such DER is treated as a separate award. The number of shares authorized for issuance under the 2015 Plan is 2,190,320. Option awards under the 2015 Plan are granted with an exercise price equal to the fair value of the Company's common stock at the date of grant. Time based option awards vest based on time, typically four years, and performance based option awards vest based on the performance criteria specified in the grant. All option awards have a ten-year contractual term. The Company recognizes compensation costs for its time based awards on a straight-line basis equal to the vesting period. The compensation cost for performance based awards is recognized on a graded vesting basis, based on the probability of achieving the performance targets over the requisite service period for the entire award. The fair value of each option award is estimated on the date of grant using a Black-Scholes valuation model that uses the assumptions noted in the following table. Expected volatilities are based on the historic volatility of a selected peer group. Expected dividends represent the dividends expected to be issued at the date of grant. The expected term of options represents the period of time that options granted are expected to be outstanding. The risk-free interest rate assumption is the U.S. Treasury rate at the date of the grant which most closely resembles the expected life of the options.

[Table of Contents](#)

The Company uses the following Black-Scholes inputs to determine the fair value of new stock option grants.

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--------------------------|-------------------------------------|------|------------------------------------|------------|
| | 2015 | 2014 | 2015 | 2014 |
| Expected volatility | 30% | — | 26 – 30% | 33 – 35% |
| Expected dividends | — | — | — | — |
| Expected life (in years) | 6.0 | — | 4.1 – 6.3 | 5.5 – 6.3 |
| Risk-free interest rate | 1.8% | — | 1.3 – 1.9% | 1.5 – 1.9% |

A summary of option activity for 2015 is presented below:

| | Time Based | Performance Based | Total | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term | Aggregate Intrinsic Value |
|---|------------------|-------------------|------------------|---------------------------------|---|---------------------------|
| Outstanding at January 1, 2015 | 1,146,509 | 384,601 | 1,531,110 | \$ 13.57 | 6.4 | \$3,979,000 |
| Options granted | 281,474 | — | 281,474 | 12.11 | | |
| Options cancelled | (30,759) | (3,904) | (34,663) | 21.33 | | |
| Options exercised | — | — | — | — | | |
| Options forfeited or expired | (312,413) | (143,737) | (456,150) | 19.25 | | |
| Outstanding at September 30, 2015 | <u>1,084,810</u> | <u>236,962</u> | <u>1,321,772</u> | 11.10 | 5.2 | \$ — |
| Vested and expected to vest at September 30, 2015 | <u>1,042,638</u> | <u>232,695</u> | <u>1,275,332</u> | 11.03 | 5.1 | \$ — |
| Exercisable at September 30, 2015 | <u>662,891</u> | <u>208,579</u> | <u>871,470</u> | 10.01 | 4.1 | \$ — |

The weighted average grant-date fair value of options granted during the nine months ended September 30, 2015 and 2014 was \$1.44 and \$2.08, respectively. The weighted average grant-date fair value of options granted during the three months ended September 30, 2015 was \$2.35. No options were granted during the three months ended September 30, 2014.

A summary of restricted stock awards activity for 2015 is presented below:

| | Time Based | Weighted Average Grant Date Fair Value |
|---|------------------|--|
| Issued and unvested at January 1, 2015 | — | \$ — |
| Granted | 1,276,700 | 6.14 |
| Vested | — | — |
| Forfeited | (184,340) | 6.27 |
| Issued and unvested at September 30, 2015 | <u>1,092,360</u> | <u>6.12</u> |

Table of Contents

Stock-based compensation expense for both time based and performance based stock options, restricted stock awards and common stock grants were recognized in the condensed consolidated statements of operations as follows:

| (in thousands) | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|-------------------------------------|--------------|------------------------------------|--------------|
| | 2015 | 2014 | 2015 | 2014 |
| Cost of goods sold | \$ 51 | \$ 32 | \$ 102 | \$104 |
| General and administrative | 417 | 151 | 1,095 | 474 |
| Sales and marketing | 71 | 34 | 186 | 116 |
| Research and development | 52 | 30 | 141 | 88 |
| Total stock-based compensation expense | <u>\$591</u> | <u>\$247</u> | <u>\$1,524</u> | <u>\$782</u> |

13. Net Income (Loss) Per Share

Basic income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period, plus the potential dilutive effect of other securities if those securities were converted or exercised. During periods in which the Company incurs net losses, both basic and diluted loss per share is calculated by dividing the net loss by the weighted average shares outstanding and potentially dilutive securities are excluded from the calculation because their effect would be antidilutive.

| (in thousands, except share and per share amounts) | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|-------------------------------------|-------------------|------------------------------------|-------------------|
| | 2015 | 2014 | 2015 | 2014 |
| Net income (loss) | \$ 5,386 | \$ (867) | \$ (18,662) | \$ (3,788) |
| Basic weighted average common shares outstanding | 30,359,516 | 18,080,968 | 22,443,257 | 18,080,496 |
| Effect of dilutive restricted stock awards | 289,911 | — | — | — |
| Effect of dilutive stock options | 112,344 | — | — | — |
| Diluted weighted average common shares outstanding | <u>30,761,771</u> | <u>18,080,968</u> | <u>22,443,257</u> | <u>18,080,496</u> |
| Basic and diluted income (loss) per common share | <u>\$ 0.18</u> | <u>\$ (0.05)</u> | <u>\$ (0.83)</u> | <u>\$ (0.21)</u> |

The weighted average number of common shares for the three and nine months ended September 30, 2015, did not include 653,322 and 2,414,132 options and unvested restricted stock, respectively, because of their antidilutive effect. The weighted average number of common shares for the three and nine months ended September 30, 2014, did not include 1,373,508 options because of their antidilutive effect.

14. Other Income (Expense), net

| (in thousands) | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|-----------------------------------|-------------------------------------|--------------|------------------------------------|----------------|
| | 2015 | 2014 | 2015 | 2014 |
| Foreign currency (losses) gains | \$(628) | \$ 82 | \$(989) | \$(311) |
| Tax indemnification income | 439 | 359 | 1,216 | 163 |
| Other income | 6 | — | 7 | — |
| Total other income (expense), net | <u>\$(183)</u> | <u>\$441</u> | <u>\$ 234</u> | <u>\$(148)</u> |

15. Legal Proceedings and Contingencies

From time to time, the Company is a party to various legal proceedings arising in the ordinary course of business. In addition, the Company has in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities, which expose it to greater risks associated with litigation, regulatory or other proceedings, as a result of which the Company could be required to pay significant fines or penalties. The outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. As of September 30, 2015, the Company had no material ongoing litigation in which the Company was a defendant or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.

On December 16, 2010, LMI filed suit against one of its insurance carriers seeking to recover business interruption losses associated with the NRU reactor shutdown and the ensuing global Moly supply shortage. The claim is the result of the shutdown of the NRU reactor in Chalk River, Ontario. The NRU reactor was off-line from May 2009 until August 2010. The defendant answered the complaint on January 21, 2011, denying substantially all of the allegations, presenting certain defenses and requesting dismissal of the case with costs and disbursements. Discovery, including international discovery and related motion practice, went on for more than three years. The defendant filed a motion for summary judgment on July 14, 2014. The Company filed a memorandum of law in opposition to defendant's motion for summary judgment on August 25, 2014. The defendant filed a reply memorandum of law in further support of its motion for summary judgment on September 15, 2014. Expert witness discovery was completed on October 31, 2014. On March 25, 2015, the United States District Court for the Southern District of New York granted defendant's motion for summary judgment. On September 4, 2015, the Company filed an appeal of the District Court decision with the United States Court of Appeals for the Second Circuit. The Company cannot be certain when, if ever, it will be able to recover for business interruption losses related to this matter and in what amount, if any.

16. Related Party Transactions

Avista, the Company's majority shareholder, provided certain advisory services to the Company pursuant to an advisory services and monitoring agreement. The Company was required to pay an annual fee of \$1.0 million and other reasonable and customary advisory fees, as applicable, paid on a quarterly basis. The initial term of the agreement was seven years. On June 25, 2015, the Company exercised its right to terminate its advisory services and monitoring agreement with Avista. In connection with such termination, the Company has paid Avista Capital Holdings, L.P. an aggregate termination fee of \$6.5 million, which is included in general and administrative expenses in the condensed consolidated statement of operations. During the three months ended September 30, 2015, the Company did not incur any costs associated with this agreement as compared to \$0.3 million for the prior year comparative period. During the nine months ended September 30, 2015, the Company incurred costs associated with this agreement totaling \$7.0 million as compared to the \$0.8 million for the prior year comparative period. At December 31, 2014, \$10,000 was included in accrued expenses. There were no amounts outstanding as of September 30, 2015.

The Company purchases inventory supplies from VWR Scientific, or VWR. Avista and certain of its affiliates are principal owners of both VWR and the Company. During each of the three and nine months ended September 30, 2015 and 2014, the Company made purchases of \$0.1 million and \$0.2 million, respectively. At September 30, 2015 and December 31, 2014, \$9,000 and \$21,000, respectively, was included in accounts payable and accrued expenses.

The Company retains Marsh for insurance brokering and risk management. Donald Bailey, brother of the Company's former President and Chief Executive Officer, Jeffrey Bailey, is head of sales for Marsh's U.S. and Canada division. During each of the nine months ended September 30, 2015 and 2014, the Company paid Marsh \$0.2 million. At both September 30, 2015 and December 31, 2014, a prepaid amount of \$43,000 was included in other current assets.

17. Segment Information

The Company reports two operating segments, U.S. and International, based on geographic customer base. The results of these operating segments are regularly reviewed by the Company's chief operating decision maker, the President and Chief Executive Officer. The Company's segments derive revenues through the manufacturing, marketing, selling and distribution of medical imaging products, focused primarily on cardiovascular diagnostic imaging. The U.S. segment comprises 79.9% and 80.2% of consolidated revenues for the three and nine months ended September 30, 2015 as compared to 78.5% and 77.8% for the prior year comparative periods and 90.9% and 90.1% of consolidated assets at September 30, 2015 and December 31, 2014, respectively. All goodwill has been allocated to the U.S. operating segment.

[Table of Contents](#)

Selected information for each business segment are as follows (in thousands):

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|------------------|------------------------------------|-------------------|
| | 2015 | 2014 | 2015 | 2014 |
| Revenues | | | | |
| U.S. | \$64,420 | \$ 64,311 | \$194,897 | \$188,679 |
| International | 14,911 | 16,253 | 44,003 | 49,823 |
| Total revenue, including inter-segment | 79,331 | 80,564 | 238,900 | 238,502 |
| Less inter-segment revenue | (5,208) | (4,882) | (16,640) | (13,871) |
| | <u>\$74,123</u> | <u>\$ 75,682</u> | <u>\$222,260</u> | <u>\$224,631</u> |
| Revenues from external customers | | | | |
| U.S. | \$59,212 | \$ 59,429 | \$178,257 | \$174,808 |
| International | 14,911 | 16,253 | 44,003 | 49,823 |
| | <u>\$74,123</u> | <u>\$ 75,682</u> | <u>\$222,260</u> | <u>\$224,631</u> |
| Operating income | | | | |
| U.S. | \$13,303 | \$ 8,174 | \$ 29,424 | \$ 23,611 |
| International | 2 | 1,009 | 587 | 3,653 |
| Total operating income, including inter-segment | 13,305 | 9,183 | 30,011 | 27,264 |
| Inter-segment operating income | 103 | 38 | 131 | 426 |
| Operating income | 13,408 | 9,221 | 30,142 | 27,690 |
| Interest expense, net | (7,100) | (10,585) | (31,599) | (31,704) |
| Loss on extinguishment of debt | — | — | (15,528) | — |
| Other income (expense), net | (183) | 441 | 234 | (148) |
| Income (loss) before income taxes | <u>\$ 6,125</u> | <u>\$ (923)</u> | <u>\$ (16,751)</u> | <u>\$ (4,162)</u> |

| | September 30, 2015 | December 31, 2014 |
|---------------------|-----------------------|----------------------|
| Total assets | | |
| U.S. | \$ 214,579 | \$ 219,129 |
| International | 21,553 | 24,024 |
| | <u>\$ 236,132</u> | <u>\$ 243,153</u> |

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

Some of the statements contained in this quarterly report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, including, in particular, statements about our plans, strategies, prospects and industry estimates are subject to risks and uncertainties. These statements identify prospective information and include words such as "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "should," "could," "predicts," "targets," "hopes" and similar expressions. Examples of forward-looking statements include, but are not limited to, statements we make regarding: (i) our outlook and expectations including, without limitation, in connection with continued market expansion and penetration for our commercial products, particularly DEFINITY in the face of increased competition; (ii) our outlook and expectations in connection with future performance of Xenon in the face of potential increased competition; (iii) our outlook and expectations related to products manufactured at JHS and Pharmeducence and global isotope supply; (iv) our outlook and expectations related to our intention to seek to engage strategic partners to assist in developing and potentially commercializing development candidates; and (v) our liquidity, including our belief that our existing cash, cash equivalents, anticipated revenues and availability under our revolving credit facility, or Revolving Facility, are sufficient to fund our existing operating expenses, capital expenditures and liquidity requirements for at least the next twelve months. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. The matters referred to in the forward-looking statements contained in this prospectus may not in fact occur. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions and the following:

- our ability to continue to increase segment penetration for DEFINITY in suboptimal echocardiograms and the increased segment competition from other echocardiography contrast agents, including Optison from GE Healthcare and Lumason from Bracco Diagnostics Inc., or Bracco;
- our ability to maintain revenues and unit volumes for Xenon in pulmonary studies and the prospect of increased competition in this generic segment;
- our dependence on key customers and group purchasing organization arrangements for our medical imaging products, and our ability to maintain and profitably renew our contracts and relationships with those key customers and group purchasing organizations, including our relationship with Cardinal Health, or Cardinal;
- our dependence upon third parties for the manufacture and supply of a substantial portion of our products;
- risks associated with the technology transfer programs to secure production of our products at alternate contract manufacturer sites, including for DEFINITY at Pharmeducence;
- risks associated with the manufacturing and distribution of our products and the regulatory requirements related thereto;
- the instability of the global Molybdenum-99, or Moly, supply;
- the dependence of certain of our customers upon third party healthcare payors and the uncertainty of third party coverage and reimbursement rates;
- uncertainties regarding the impact of U.S. healthcare reform on our business, including related reimbursements for our current and potential future products;
- our being subject to extensive government regulation and our potential inability to comply with those regulations;
- potential liability associated with our marketing and sales practices;
- the occurrence of any side effects with our products;
- our exposure to potential product liability claims and environmental liability;
- risks associated with our lead agent in development, flurpiridaz F 18, including our ability to:
 - attract strategic partners to successfully complete the Phase 3 clinical program and possibly commercialize the agent;
 - obtain FDA approval; and
 - gain post-approval market acceptance and adequate reimbursement;

Table of Contents

- risks associated with being able to negotiate in a timely manner relationships with potential strategic partners to advance our other development programs on acceptable terms, or at all;
- the extensive costs, time and uncertainty associated with new product development, including further product development relying on external development partners;
- our inability to introduce new products and adapt to an evolving technology and diagnostic landscape;
- our inability to protect our intellectual property and the risk of claims that we have infringed on the intellectual property of others;
- risks associated with prevailing economic conditions and financial, business and other factors beyond our control;
- risks associated with our international operations;
- our inability to adequately protect our facilities, equipment and technology infrastructure;
- our inability to hire or retain skilled employees and key personnel;
- risks related to our outstanding indebtedness and our ability to satisfy those obligations; and
- costs and other risks associated with the Sarbanes-Oxley Act and the Dodd-Frank Act risks related to the ownership of our common stock.

Factors that could cause or contribute to such differences include, but are not limited to, those that are discussed in other documents we file with the Securities and Exchange Commission. Any forward-looking statement made by us in this quarterly report speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

The following discussion and analysis of our financial condition and results of operations should be read together with the condensed consolidated financial statements and the related notes included in Item 1 of this Quarterly Report on Form 10-Q as well as the other factors described in "Risk Factors" in the Prospectus.

Overview

We are a global leader in developing, manufacturing, selling and distributing innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. Our agents are routinely used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. Clinicians use our imaging agents and products across a range of imaging modalities, including echocardiography, nuclear imaging and MRI. We believe that the resulting improved diagnostic information enables healthcare providers to better detect and characterize, or rule out, disease, potentially achieving improved patient outcomes, reducing patient risk and limiting overall costs for payers and the entire healthcare system.

Our commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, technologists and sonographers working in a variety of clinical settings. We sell our products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies, and, in certain circumstances, wholesalers.

We sell our products globally and have operations in the United States, Puerto Rico, Canada and Australia and distribution relationships in Europe, Asia Pacific and Latin America.

Our Products

Our principal products include the following:

DEFINITY is an ultrasound contrast agent used in ultrasound exams of the heart, also known as echocardiography exams. DEFINITY contains perflutren-containing lipid microspheres and is indicated in the United States for use in patients with suboptimal echocardiograms to assist in imaging the left ventricular chamber and left endocardial border of the heart in ultrasound procedures. We launched DEFINITY in 2001, and its last patent in the United States will currently expire in 2021 and in numerous foreign jurisdictions in 2019. We also have an active next generation development program for this agent.

[Table of Contents](#)

TechneLite is a technetium generator which provides the essential nuclear material used by radiopharmacies to radiolabel Cardiolite, Neurolite and other technetium-based radiopharmaceuticals used in nuclear medicine procedures. TechneLite uses Moly as its main active ingredient.

Xenon is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also cerebral blood flow. Xenon is manufactured by a third party and packaged by us.

Sales of our contrast agent, DEFINITY, are made in the United States and Canada through our sales team of approximately 80 employees. In the United States, our nuclear imaging products, including TechneLite, Xenon, Cardiolite and Neurolite, are primarily distributed through commercial radiopharmacies, the majority of which are controlled by or associated with Cardinal, UPPI, GE Healthcare and Triad. A small portion of our nuclear imaging product sales in the United States are made through our direct sales force to hospitals and clinics that maintain their own in-house radiopharmaceutical capabilities. Outside the United States, we own four radiopharmacies in Canada and two radiopharmacies in Australia and one in Puerto Rico. In Europe, Asia Pacific and Latin America, we rely on third party distributors to market, sell and distribute our nuclear imaging and contrast agent products, either on a country-by-country basis or on a multicountry regional basis.

The following table sets forth our revenue derived from our principal products:

| (dollars in thousands) | Three Months Ended September 30, | | | | Nine Months Ended September 30, | | | |
|------------------------|----------------------------------|---------------|-----------------|---------------|---------------------------------|---------------|------------------|---------------|
| | 2015 | % | 2014 | % | 2015 | % | 2014 | % |
| DEFINITY | \$28,883 | 39.0% | \$24,261 | 32.1% | \$ 82,977 | 37.3% | \$ 70,136 | 31.2% |
| TechneLite | 17,223 | 23.2 | 23,612 | 31.2 | 55,445 | 24.9 | 70,178 | 31.2 |
| Xenon | 12,723 | 17.2 | 8,916 | 11.8 | 37,965 | 17.1 | 27,525 | 12.3 |
| Other | 15,294 | 20.6 | 18,893 | 24.9 | 45,873 | 20.7 | 56,792 | 25.3 |
| Revenues | <u>\$74,123</u> | <u>100.0%</u> | <u>\$75,682</u> | <u>100.0%</u> | <u>\$222,260</u> | <u>100.0%</u> | <u>\$224,631</u> | <u>100.0%</u> |

Key Factors Affecting Our Results

Our business and financial performance have been, and continue to be, affected by the following:

Growth of DEFINITY

We believe the market opportunity for our contrast agent, DEFINITY, remains significant. DEFINITY is currently our fastest growing and highest margin commercial product. We believe that DEFINITY sales will continue to grow and that DEFINITY will constitute a greater share of our overall product mix. As a result of DEFINITY's continued growth, we believe that our gross profit will increase, and our gross margin will continue to expand. As we better educate the physician and healthcare provider community about the benefits and risks of this product, we believe we will experience further penetration of suboptimal echocardiograms.

Prior to the supply issues with Ben Venue Laboratories, or BVL, in 2012, sales of DEFINITY continually increased year-over-year since June 2008, when the boxed warning on DEFINITY was modified. Unit sales of DEFINITY had decreased substantially in late 2007 and early 2008 as a result of an FDA request in October 2007 that we and GE Healthcare, which distributes Optison, a competitor to DEFINITY, add a boxed warning to their products to notify physicians and patients about potentially serious safety concerns or risks posed by the products. However, in May 2008, the FDA boxed warning was modified in response to the substantial advocacy efforts of prescribing physicians. In October 2011, we received FDA approval of further favorable modifications to the DEFINITY label, including: further relaxing the boxed warning; eliminating the sentence in the Indication and Use section "The safety and efficacy of DEFINITY with exercise stress or pharmacologic stress testing have not been established" (previously added in October 2007 in connection with the imposition of the box warning); and including summary data from the post-approval CaRES (Contrast echocardiography Registry for Safety Surveillance) safety registry and the post-approval pulmonary hypertension study. Bracco's ultrasound contrast agent, Lumason, has substantially similar labeling as DEFINITY and Optison. The future growth of our DEFINITY sales will be dependent on our ability to continue to increase segment penetration for DEFINITY in suboptimal echocardiograms and, as discussed below in "—Inventory Supply," on the ability of JHS, and, if approved Pharmedica, to continue to manufacture and release DEFINITY on a timely and consistent basis. See "Prospectus—Risk Factors—The growth of our business is substantially dependent on increased market penetration for the appropriate use of DEFINITY in suboptimal echocardiograms."

There are three echocardiography contrast agents approved by the FDA for sale in the U.S.—DEFINITY which as of December 2014 had an approximately 78% segment share, Optison, and Lumason approved by the FDA in October 2014. Lumason is known as SonoVue outside of the U.S. and is already approved for sale in Europe and certain Asian markets, including China, Japan and Korea. While we believe that additional promotion in the U.S. echocardiography segment will help raise awareness around the value that

[Table of Contents](#)

echocardiography contrast brings and potentially increase the overall contrast penetration rate, if Bracco successfully commercializes Lumason in the U.S. without otherwise increasing the overall usage of ultrasound contrast agents, our own growth expectations for DEFINITY revenue, gross profit and gross margin may have to be adjusted.

Competition for Xenon

Xenon (Xe 133) gas for lung ventilation diagnosis is our third largest product by revenue. Historically, several companies sold packaged Xenon as a pulmonary imaging agent in the U.S., but since 2010 we have been the only supplier of this imaging agent in the U.S. We understand that a radiopharmaceutical manufacturer is now seeking regulatory approval from the FDA to sell packaged Xenon in the U.S. If that manufacturer receives FDA approval and begins to sell packaged Xenon in the U.S., depending upon the pricing, extent of availability and market penetration of the new offering, we believe we could experience substantial volume loss and price erosion with existing Xenon customers who are not subject to price or volume commitments, such as Cardinal Health, historically our largest Xenon customer. Although we intend to compete vigorously in the market for this important imaging agent, we believe that these developments could have a material adverse effect on our business, results of operations, financial condition and cash flows. See “Part II—Item 1A—Risk Factors—We face potential supply and demand challenges for Xenon.”

Inventory Supply

Our products consist of contrast imaging agents and radiopharmaceuticals (including technetium generators). We obtain a substantial portion of our imaging agents from third party suppliers. JHS is currently our sole source manufacturer of DEFINITY and Neurolite and we have ongoing technology transfer activities at JHS for our Cardiolite product supply. In the meantime, our Cardiolite product supply is manufactured by a single manufacturer. Until JHS is approved by certain foreign regulatory authorities to manufacture certain of our products, we will face continued limitations on where we can sell those products outside of the United States.

In addition to JHS, we are also currently working to secure additional alternative suppliers for our key products as part of our ongoing supply chain diversification strategy. On November 12, 2013, we entered into a Manufacturing and Supply Agreement with Pharmalucence to manufacture and supply DEFINITY. We currently target filing for FDA approval to manufacture DEFINITY at Pharmalucence in 2016. For the balance of 2015, we currently anticipate higher levels of technology transfer costs, which are period expenses associated with our various manufacturing initiatives, as our contract manufacturer-related activities intensify.

Radiopharmaceuticals are decaying radioisotopes with half-lives ranging from a few hours to several days. These products cannot be kept in inventory because of their limited useful lives and are subject to just-in-time manufacturing, processing and distribution, which takes place at our North Billerica, Massachusetts facility.

Global Isotope Supply

Currently, our largest supplier of Moly and our only supplier of Xenon is Nordion, which relies on the NRU reactor in Chalk River, Ontario. For Moly, we currently have a supply agreement with Nordion that runs through December 31, 2015, subject to certain early termination provisions, and supply agreements with NTP of South Africa, ANSTO of Australia, and IRE of Belgium, each running through December 31, 2017. For Xenon, we have a purchase order relationship with Nordion. The Canadian government requires the NRU reactor to shut down for at least four weeks at least once a year for inspection and maintenance. The 2015 shutdown period ran from April 13, 2015 until May 12, 2015, and we were able to source all of our standing order customer demand for Moly during this time period from our other suppliers. However, because Xenon is a by-product of the Moly production process and is currently captured only by NRU, for approximately two weeks during this shutdown period, we were not able to supply all of our standing order customer demand for Xenon. Because the month-long NRU shutdown was fully anticipated in our 2015 budgeting process, the shutdown did not have a material adverse effect on our 2015 results of operations, financial condition and cash flows.

We believe we are well-positioned with our current supply partners to have a secure supply of Moly, including low-enriched uranium, or LEU, Moly, when the NRU reactor transitions in October 2016 from providing regular supply of medical isotopes to providing only emergency back-up supply medical isotopes through March 2018. ANSTO has under construction, in cooperation with NTP, a new Moly processing facility that ANSTO believes will expand its production capacity by approximately 2.5 times, with expanded commercial production planned to start in the latter part of 2016. In addition, IRE is currently in the process of expanding its production capability by up to 50%, and IRE expects this capacity expansion to be approved by its regulatory body by 2016. The new ANSTO and IRE production capacity is expected to replace the NRU's current routine production. In January 2015, we announced entering into a new strategic agreement with IRE for the future supply of Xenon. Under the terms of the agreement, IRE will provide bulk Xenon to us for processing and finishing once development work has been completed and all necessary regulatory approvals have been obtained. We currently estimate commercial production will occur in 2016. If we are not able to begin providing commercial quantities of Xenon prior to the NRU reactor's supply transition in October 2016, there may be a period of time during which we are not able to offer Xenon in our portfolio of commercial products. See “Part II—Item 1A—Risk Factors—We face potential supply and demand challenges for Xenon.”

[Table of Contents](#)

Demand for TechneLite

Since the global Moly supply shortage in 2009 to 2010, we have experienced reduced demand for TechneLite generators from pre-shortage levels even though volume has increased in absolute terms from levels during the shortage following the return of our normal Moly supply in August 2010. However, we do not know if overall industry demand for technetium will ever return to pre-shortage levels. See “Prospectus—Risk Factors—The Moly supply shortage caused by the 2009-10 NRU reactor shutdown has had a negative effect on the demand for some of our products, which will likely continue in the future.”

Separate from the Moly supply shortage, we believe there has also been a decline in the MPI study market because of industry-wide cost containment initiatives that have resulted in a transition of where imaging procedures are performed, from free-standing imaging centers to the hospital setting. While the total number of patient studies has not returned to pre-shortage levels, the total MPI market has been essentially flat for the period 2011 through 2014.

In November 2014, CMS announced the 2015 final Medicare payment rules for hospital outpatient settings. Under the final rules, each technetium dose produced from a generator for a diagnostic procedure in a hospital outpatient setting is reimbursed by Medicare at a higher rate if that technetium dose is produced from a generator containing Moly sourced from at least 95 percent LEU. We currently understand that CMS expects to continue this incentive program for the foreseeable future. In January 2013, we began to offer a TechneLite generator which contains Moly sourced from at least 95 percent LEU and which satisfies the requirements for reimbursement under this incentive program. Although demand for LEU generators appears to be growing, we cannot predict when, or if, this incremental reimbursement for LEU Moly generators will result in a material increase in our generator sales.

Cardinal Supply Agreements

Our written supply agreements with Cardinal relating to TechneLite generators, Xenon, NeuroLite, Cardiolite and certain other products expired in accordance with their terms on December 31, 2014. Following extended discussions with Cardinal that have not yet resulted in one or more new written supply agreements, we are currently accepting and fulfilling product orders from Cardinal on a purchase order basis at list price. We cannot predict the volumes or product mix Cardinal will continue to order and purchase, and such volumes and product mix may vary over time. In the absence of written supply agreements with Cardinal, in early 2015, our sales volumes with Cardinal began to transition from previous historical levels to new, lower levels, but at substantially higher prices. This gave us a revenue and margin benefit in the first quarter of 2015. Some of the volume that we previously sold to Cardinal has shifted to sales to other of our radiopharmacy customers. We currently anticipate the benefit we experienced in the first quarter of 2015 from this change will continue to moderate in future quarters as we do not have written supply agreements with Cardinal.

While future levels of revenue and profit contribution associated with Cardinal cannot be predicted at this time because such amounts depend on future unit sales volumes, product mix and pricing to Cardinal, we currently anticipate that overall quarterly levels for the remainder of 2015 will be lower than those experienced during the first quarter of 2015 and during the respective year-ago periods. We further anticipate this change in contractual status will continue to favorably impact our gross profit percentage versus respective year-ago periods, though not to the extent experienced during the first quarter of 2015. The future favorable impact to our gross profit percentage will depend on ultimate levels of unit volume and product mix ordered by this customer in future periods. See “Prospectus—Risk Factors—In the United States, we are heavily dependent on a few large customers and group purchasing organization arrangements to generate a majority of our revenues for our medical imaging products. Outside of the United States, we rely on distributors to generate a substantial portion of our revenues.” See “Part II—Item 1A—Risk Factors —We face potential supply and demand challenges for Xenon.”

Research and Development Expenses

To remain a leader in the marketplace, we have historically made substantial investments in new product development. As a result, the positive contributions of those internally funded R&D programs have been a key factor in our historical results and success. In March 2013, we began to implement a strategic shift in how we fund our important R&D programs. We have reduced our internal R&D resources while at the same time we are seeking to engage strategic partners to assist us in the further development and commercialization of our important agents in development, including flurpiridaz F 18, 18F LMI 1195 and LMI 1174.

In November 2014, we announced our plans to decommission certain long-lived assets associated with our R&D operations in the United States. We expected the decommissioning to begin in the second half of 2015. As a result, we revised our estimates of the remaining useful lives of the affected long-lived assets to seven months.

[Table of Contents](#)

During the second quarter of 2015, we halted our decommissioning plans until an indefinite date. As a result, we revised our estimates of the remaining useful lives of the affected long-lived assets back to its original remaining useful life effective April 1, 2015. This resulted in a decrease in depreciation expense of \$3.7 million during the quarter ended June 30, 2015, as compared to the quarter ended March 31, 2015, and is included in R&D expenses in the condensed consolidated statement of operations.

At September 30, 2015 and December 31, 2014, the net book value of these assets totaled \$4.4 million and \$7.4 million, respectively.

Segments

We report our results of operations in two operating segments: United States and International. We generate a greater proportion of our revenue and net income in the United States segment, which consists of all regions of the United States with the exception of Puerto Rico. We expect our percentage of revenue and net income derived from our International segment to continue to increase in future periods as we continue to expand globally.

Executive Overview

Our results in the three and nine months ended September 30, 2015 reflect the following:

- increased revenues and segment penetration for DEFINITY in the suboptimal echocardiogram segment as a result of our sales efforts and sustained availability of product supply;
- increased revenues for Xenon, mainly the result of higher selling prices, offset in part by mix shift among certain sales channels;
- decreased revenues from our TechneLite generators in absence of Cardinal agreements;
- lower international revenues across product lines because of unfavorable foreign exchange and competitive pressures;
- increased depreciation over the prior year period associated with the scheduled decommissioning of certain long-lived assets;
- \$15.5 million loss on extinguishment of debt costs related to the redemption of LMI's outstanding Notes;
- \$6.5 million payment for the termination of our advisory services and monitoring agreement with Avista;
- \$3.3 million in additional interest payments to redeem the Notes on July 30, 2015; and
- decreased interest expense due to the refinancing of long-term debt.

Results of Operations

| <u>(dollars in thousands)</u> | <u>For the Three Months</u> <u>Ended September 30,</u> | | <u>For the Nine Months</u> <u>Ended September 30,</u> | |
|--------------------------------------|---|-----------------|--|-------------------|
| | <u>2015</u> | <u>2014</u> | <u>2015</u> | <u>2014</u> |
| Revenues | \$74,123 | \$ 75,682 | \$222,260 | \$224,631 |
| Cost of goods sold | 40,418 | 44,044 | 120,119 | 131,873 |
| Gross profit | 33,705 | 31,638 | 102,141 | 92,758 |
| Operating expenses | | | | |
| Sales and marketing expenses | 8,633 | 8,327 | 26,934 | 27,227 |
| General and administrative expenses | 9,206 | 11,041 | 33,773 | 28,883 |
| Research and development expenses | 2,458 | 3,049 | 11,292 | 8,958 |
| Total operating expenses | 20,297 | 22,417 | 71,999 | 65,068 |
| Operating income | 13,408 | 9,221 | 30,142 | 27,690 |
| Interest expense, net | (7,100) | (10,585) | (31,599) | (31,704) |
| Loss on extinguishment of debt | — | — | (15,528) | — |
| Other income (expense), net | (183) | 441 | 234 | (148) |
| Income (loss) before income taxes | 6,125 | (923) | (16,751) | (4,162) |
| Provision (benefit) for income taxes | 739 | (56) | 1,911 | (374) |
| Net income (loss) | <u>\$ 5,386</u> | <u>\$ (867)</u> | <u>\$ (18,662)</u> | <u>\$ (3,788)</u> |

[Table of Contents](#)

Revenues

Revenues are summarized as follows:

| (dollars in thousands) | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|-------------------------------------|-------------------------------------|-----------------|------------------------------------|------------------|
| | 2015 | 2014 | 2015 | 2014 |
| United States | | | | |
| DEFINITY | \$28,323 | \$23,764 | \$ 81,333 | \$ 68,768 |
| TechneLite | 14,557 | 20,879 | 47,367 | 61,602 |
| Xenon | 12,713 | 8,914 | 37,937 | 27,519 |
| Other | 3,619 | 5,872 | 11,620 | 16,919 |
| Total U.S. revenues | <u>\$59,212</u> | <u>\$59,429</u> | <u>\$178,257</u> | <u>\$174,808</u> |
| International | | | | |
| DEFINITY | \$ 560 | \$ 497 | \$ 1,644 | \$ 1,368 |
| TechneLite | 2,666 | 2,733 | 8,078 | 8,576 |
| Xenon | 10 | 2 | 28 | 6 |
| Other | 11,675 | 13,021 | 34,253 | 39,873 |
| Total International revenues | <u>\$14,911</u> | <u>\$16,253</u> | <u>\$ 44,003</u> | <u>\$ 49,823</u> |
| Revenues | <u>\$74,123</u> | <u>\$75,682</u> | <u>\$222,260</u> | <u>\$224,631</u> |

Total revenues decreased \$1.6 million, or 2.1%, to \$74.1 million in the three months ended September 30, 2015, as compared to \$75.7 million in the three months ended September 30, 2014. U.S. segment revenue decreased \$0.2 million, or 0.4%, to \$59.2 million in the three months ended September 30, 2015, as compared to \$59.4 million in the prior year period. The International segment revenues decreased \$1.4 million, or 8.3%, to \$14.9 million in the three months ended September 30, 2015, as compared to \$16.3 million in the prior year period.

Total revenues decreased \$2.3 million, or 1.1%, to \$222.3 million in the nine months ended September 30, 2015, as compared to \$224.6 million in the nine months ended September 30, 2014. U.S. segment revenue increased \$3.5 million, or 2.0%, to \$178.3 million in the nine months ended September 30, 2015, as compared to \$174.8 million in the prior year period. The International segment revenues decreased \$5.8 million, or 11.7%, to \$44.0 million in the nine months ended September 30, 2015, as compared to \$49.8 million in the prior year period.

The decrease in U.S. segment revenues for the three months ended September 30, 2015, as compared to the prior year period is primarily due to a decrease of \$6.3 million in TechneLite driven by lower volumes, a decrease of \$0.8 million in Neurolite driven by lower volumes and a decrease in license revenue of approximately of \$1.0 million as a result of a contract ending in December 2014 that had contained a license fee that was recognized on a straight-line basis over the term of the agreement. Offsetting these decreases was an increase of \$3.8 million increase in Xenon primarily as a result of higher selling prices and an increase of \$4.6 million in DEFINITY driven primarily by higher unit volumes.

The increase in U.S. segment revenues for the nine months ended September 30, 2015, as compared to the prior year period is primarily due to an increase of \$12.6 million in DEFINITY driven primarily by higher unit volumes and an increase of \$10.4 million increase in Xenon primarily as a result of higher selling prices. Offsetting these increases was a decrease of \$14.2 million TechneLite driven by lower volumes, a decrease in license revenue of approximately of \$2.9 million as a result of a contract ending in December 2014 that had contained a license fee that was recognized on a straight-line basis over the term of the agreement, \$1.6 million in Neurolite driven by lower volumes and \$1.2 million in Thallium driven by lower volumes.

The decrease in the International segment revenues for the three months ended September 30, 2015, as compared to the prior year period is primarily due to \$2.3 million unfavorable foreign exchange and \$0.4 million decrease in Cardiolite revenues as a result of competitive pressures. This was offset, in part, by \$0.7 million in other marketed products, \$0.4 million increase in TechneLite driven by volumes and \$0.2 million in DEFINITY driven by increased volume.

Table of Contents

The decrease in the International segment revenues for the nine months ended September 30, 2015, as compared to the prior year period is primarily due to \$5.2 million unfavorable foreign exchange and \$2.0 million decrease in Cardiolite revenues as a result of competitive pressures. This was offset, in part, by \$0.5 million increase in TechnoLite driven by volumes, \$0.5 million in DEFINITY driven by increased volume and \$0.3 million in other marketed products.

Rebates and Allowances

Estimates for rebates and allowances represent our estimated obligations under contractual arrangements with third parties. Rebate accruals and allowances are recorded in the same period the related revenue is recognized, resulting in a reduction to revenue and the establishment of a liability which is included in accrued expenses. These rebates result from performance-based offers that are primarily based on attaining contractually specified sales volumes and growth, Medicaid rebate programs for certain products, administrative fees of group purchasing organizations, royalties and certain distributor related commissions. The calculation of the accrual for these rebates and allowances is based on an estimate of the third party's buying patterns and the resulting applicable contractual rebate or commission rate(s) to be earned over a contractual period.

An analysis of the amount of, and change in, reserves is summarized as follows:

| (dollars in thousands) | Rebates | Allowances | Total |
|---|-----------------|-------------------|-----------------|
| Balance, as of January 1, 2014 | \$ 1,739 | \$ 20 | \$ 1,759 |
| Current provisions relating to revenues in current year | 5,773 | 310 | 6,083 |
| Adjustments relating to prior years' estimate | (18) | — | (18) |
| Payments/credits relating to revenues in current year | (4,264) | (284) | (4,548) |
| Payments/credits relating to revenues in prior years | <u>(1,066)</u> | <u>(20)</u> | <u>(1,086)</u> |
| Balance, as of December 31, 2014 | 2,164 | 26 | 2,190 |
| Current provisions relating to revenues in current year | 4,741 | 278 | 5,019 |
| Adjustments relating to prior years' estimate | (85) | (9) | (94) |
| Payments/credits relating to revenues in current year | (3,138) | (242) | (3,380) |
| Payments/credits relating to revenues in prior years | <u>(1,390)</u> | <u>(17)</u> | <u>(1,407)</u> |
| Balance, as of September 30, 2015 | <u>\$ 2,292</u> | <u>\$ 36</u> | <u>\$ 2,328</u> |

Accrued sales rebates were approximately \$2.3 million and \$2.2 million at September 30, 2015 and December 31, 2014, respectively. The \$0.1 million increase in accrued sales rebates is primarily due to a rebate program associated with the Quadramet product.

Costs of Goods Sold

Cost of goods sold consists of manufacturing, distribution, intangible asset amortization and other costs related to our commercial products. In addition, it includes the write-off of excess and obsolete inventory.

Cost of goods sold is summarized as follows:

| (dollars in thousands) | Three Months | | Nine Months | |
|-------------------------------|----------------------------|-----------------|----------------------------|------------------|
| | Ended September 30, | 2014 | Ended September 30, | 2014 |
| | 2015 | | 2015 | 2014 |
| United States | \$26,930 | \$31,791 | \$ 81,360 | \$ 95,047 |
| International | 13,488 | 12,253 | 38,759 | 36,826 |
| Total Cost of Goods Sold | <u>\$40,418</u> | <u>\$44,044</u> | <u>\$120,119</u> | <u>\$131,873</u> |

Total cost of goods sold decreased \$3.6 million, or 8.2%, to \$40.4 million in the three months ended September 30, 2015, as compared to \$44.0 million in the three months ended September 30, 2014. U.S. segment cost of goods sold decreased approximately \$4.9 million, or 15.3%, to \$26.9 million in the three months ended September 30, 2015, as compared to \$31.8 million in the prior year period. For the three months ended September 30, 2015, the International segment cost of goods sold increased \$1.2 million, or 10.1%, to \$13.5 million, as compared to \$12.3 million in the prior year period.

Table of Contents

Total cost of goods sold decreased \$11.8 million, or 8.9%, to \$120.1 million in the nine months ended September 30, 2015, as compared to \$131.9 million in the nine months ended September 30, 2014. U.S. segment cost of goods sold decreased approximately \$13.6 million, or 14.4%, to \$81.4 million in the nine months ended September 30, 2015, as compared to \$95.0 million in the prior year period. For the nine months ended September 30, 2015, the International segment cost of goods sold increased \$1.9 million, or 5.2%, to \$38.8 million, as compared to \$36.8 million in the prior year period.

The decrease in the U.S. segment cost of goods sold for the three months ended September 30, 2015 over the prior year period is primarily due to a decrease of \$5.1 million in the cost of goods associated with TechneLite due to lower material costs and lower sales unit volumes. In addition, there was a \$1.3 million decrease in Thallium cost of goods due to lower unit volumes sold. Offsetting these decreases were a \$1.4 million increase in DEFINITY cost of goods due to higher sales unit volumes and a \$0.9 million increase in Xenon cost of goods due to an increase in material costs.

The decrease in the U.S. segment cost of goods sold for the nine months ended September 30, 2015 over the prior year period is primarily due to a decrease of \$13.4 million in the cost of goods associated with TechneLite due to lower material costs and lower sales unit volumes. In addition, there was a \$3.0 million decrease in NeuroLite cost of goods due to lower unit volumes sold and lower technology transfer costs due to extensive technology transfer activities with JHS in the prior year period. We also experienced a decrease of \$3.6 million in the cost of goods with Thallium due to lower unit volumes sold. Offsetting these decreases were a \$4.7 million increase in DEFINITY cost of goods due to higher sales unit volumes and higher technology transfer costs and a \$2.3 million increase in Xenon cost of goods due to an increase in material costs.

The increase in the International segment cost of goods sold in the three months ended September 30, 2015, as compared to the prior year period, is primarily due to approximately \$1.9 million in manufacturing costs for certain products as well as \$0.5 million driven by higher sales volumes. Offsetting these increases was a \$1.2 million favorable foreign exchange.

The increase in the International segment cost of goods sold in the nine months ended September 30, 2015, as compared to the prior year period, is primarily due to approximately \$4.8 million in manufacturing costs for certain products. Offsetting these increases was a \$2.6 million favorable foreign exchange as well as \$0.3 million driven by lower sales volumes.

Gross Profit

| (dollars in thousands) | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|------------------------|-------------------------------------|-----------------|------------------------------------|-----------------|
| | 2015 | 2014 | 2015 | 2014 |
| United States | \$32,282 | \$27,638 | \$ 96,897 | \$79,761 |
| International | 1,423 | 4,000 | 5,244 | 12,997 |
| Total Gross Profit | <u>\$33,705</u> | <u>\$31,638</u> | <u>\$102,141</u> | <u>\$92,758</u> |

Total gross profit increased \$2.1 million, or 6.5%, to \$33.7 million in the three months ended September 30, 2015, as compared to \$31.6 million in the three months ended September 30, 2014. U.S. segment gross profit increased \$4.7 million, or 16.8%, to \$32.3 million in the three months ended September 30, 2015, as compared to \$27.6 million in the prior year period. For the three months ended September 30, 2015, the International segment gross profit decreased \$2.6 million, or 64.4%, to \$1.4 million, as compared to \$4.0 million in the prior year period.

Total gross profit increased \$9.4 million, or 10.1%, to \$102.1 million in the nine months ended September 30, 2015, as compared to \$92.8 million in the nine months ended September 30, 2014. U.S. segment gross profit increased \$17.1 million, or 21.5%, to \$96.9 million in the nine months ended September 30, 2015, as compared to \$79.8 million in the prior year period. For the nine months ended September 30, 2015, the International segment gross profit decreased \$7.8 million, or 59.7%, to \$5.2 million, as compared to \$13.0 million in the prior year period.

The increase in the U.S. segment gross profit for the three months ended September 30, 2015 over the prior year period is primarily due to a \$3.2 million increase in DEFINITY gross profit due to higher unit volumes and a \$2.9 million increase for Xenon due to higher selling price. Offsetting these increases was a \$1.3 million decrease in Technelite gross profit due to less unit volumes.

The increase in the U.S. segment gross profit for the nine months ended September 30, 2015 over the prior year period is primarily due to an \$8.1 million increase in Xenon gross profit due to higher selling price and DEFINITY gross profit increased \$7.9 million due to higher unit volumes. In addition Thallium gross profit increased by \$2.3 million primarily due to a higher average selling price and NeuroLite gross profit increased by \$1.4 million due to lower technology transfer costs. Offsetting these increases was a decrease in license revenue of \$2.8 million as a result of a contract ending in December 2014 that had contained a license fee that was recognized on a straight-line basis over the term of the agreement.

[Table of Contents](#)

The decrease in the International segment gross profit for the three months ended September 30, 2015 over the prior year period is primarily due a \$1.9 million increase in manufacturing costs for certain products. This decrease is also driven by an unfavorable foreign exchange impact of \$1.1 million. Offsetting these decreases was a \$0.4 million increase driven by higher sales volume.

The decrease in the International segment gross profit for the nine months ended September 30, 2015 over the prior year period is primarily due to a \$4.8 million increase in manufacturing costs for certain products. This decrease is also driven by an unfavorable foreign exchange impact of \$2.6 million and a \$0.4 million decrease due to lower average selling prices as a result of increased competitive pressures.

Sales and Marketing

| (dollars in thousands) | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---------------------------|-------------------------------------|-----------------|------------------------------------|-----------------|
| | 2015 | 2014 | 2015 | 2014 |
| United States | \$ 7,840 | \$ 7,299 | \$24,192 | \$23,897 |
| International | 793 | 1,028 | 2,742 | 3,330 |
| Total Sales and Marketing | <u>\$ 8,633</u> | <u>\$ 8,327</u> | <u>\$26,934</u> | <u>\$27,227</u> |

Sales and marketing expenses consist primarily of salaries and other related costs for personnel in field sales, marketing, business development and customer service functions. Other costs in sales and marketing expenses include the development and printing of advertising and promotional material, professional services, market research and sales meetings.

Total sales and marketing expenses increased \$0.3 million, or 3.7%, to \$8.6 million in the three months ended September 30, 2015, as compared to \$8.3 million in the three months ended September 30, 2014. In the U.S. segment, sales and marketing expense increased \$0.5 million, or 7.4%, to \$7.8 million in the three months ended September 30, 2015, as compared to \$7.3 million in the prior year period. In the International segment, sales and marketing expense decreased \$0.2 million, or 22.9%, to \$0.8 million in the three months ended September 30, 2015, as compared to \$1.0 million in the prior year period.

Total sales and marketing expenses decreased \$0.3 million, or 1.1%, to \$26.9 million in the nine months ended September 30, 2015, as compared to \$27.2 million in the nine months ended September 30, 2014. In the U.S. segment, sales and marketing expense increased \$0.3 million, or 1.2%, to \$24.2 million in the nine months ended September 30, 2015, as compared to \$23.9 million in the prior year period. In the International segment, sales and marketing expense decreased \$0.6 million, or 17.7%, to \$2.7 million in the nine months ended September 30, 2015, as compared to \$3.3 million in the prior year period.

The increase in the U.S. segment sales and marketing expenses for the three months ended September 30, 2015 over the prior year period is primarily due to increased market research, sales force meetings, and trainings.

The increase in the U.S. segment sales and marketing expenses for the nine months ended September 30, 2015 over the prior year period is primarily due to increased headcount and related expenses offset, in part, by timing related to marketing research activities as well as lower FDA fees.

The decrease in the International segment sales and marketing expenses for the three and nine months ended September 30, 2015 over the prior year period is primarily due to lower headcount and a favorable foreign exchange impact.

General and Administrative

| (dollars in thousands) | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|----------------------------------|-------------------------------------|------------------|------------------------------------|-----------------|
| | 2015 | 2014 | 2015 | 2014 |
| United States | \$ 8,792 | \$ 10,561 | \$32,425 | \$27,201 |
| International | 414 | 480 | 1,348 | 1,682 |
| Total General and Administrative | <u>\$ 9,206</u> | <u>\$ 11,041</u> | <u>\$33,773</u> | <u>\$28,883</u> |

[Table of Contents](#)

General and administrative expenses consist of salaries and other related costs for personnel in executive, finance, legal, information technology and human resource functions. Other costs included in general and administrative expenses are professional fees for information technology services, external legal fees, consulting and accounting services as well as bad debt expense, certain facility and insurance costs, including director and officer liability insurance.

Total general and administrative expenses decreased \$1.8 million, or 16.6%, to \$9.2 million in the three months ended September 30, 2015, as compared to \$11.0 million in the three months ended September 30, 2014. In the U.S. segment, general and administrative expense decreased \$1.8 million, or 16.8%, to \$8.8 million in the three months ended September 30, 2015, as compared to \$10.6 million in the prior year period. In the International segment, general and administrative expense decreased \$0.1 million, or 13.8%, to \$0.4 million in the three months ended September 30, 2015, as compared to \$0.5 million in the prior year period.

Total general and administrative expenses increased \$4.9 million, or 16.9%, to \$33.8 million in the nine months ended September 30, 2015, as compared to \$28.9 million in the nine months ended September 30, 2014. In the U.S. segment, general and administrative expense increased \$5.2 million, or 19.2%, to \$32.4 million in the nine months ended September 30, 2015, as compared to \$27.2 million in the prior year period. In the International segment, general and administrative expense decreased \$0.3 million, or 19.9%, to \$1.4 million in the nine months ended September 30, 2015, as compared to \$1.7 million in the prior year period.

The decrease in the U.S. segment general and administrative expenses for the three months ended September 30, 2015 over the prior year period is primarily due to \$2.3 million write-off of deferred initial public company offering costs in the prior year, offset, in part, by increased insurance associated with the effective public company offering in June 2015 and increased stock compensation costs.

The increase in the U.S. segment general and administrative expenses for the nine months ended September 30, 2015 over the prior year period is primarily due to the \$6.5 million termination fee paid to terminate the advisory services and monitoring agreement with Avista, increases in insurance associated with the effective public company offering in June 2015 and increased stock compensation costs. This was offset by higher costs in the prior period due to \$2.3 million write-off of deferred initial public company offering costs.

The decrease in the International segment general and administrative expenses for the three and nine months ended September 30, 2015 over the prior year period is primarily due to lower headcount, lower professional fees, lower bad debt expense and a favorable foreign exchange impact.

Research and Development

| (dollars in thousands) | Three Months | | Nine Months | |
|---------------------------|--------------------------|-----------------|--------------------------|----------------|
| | Ended September 30, 2015 | 2014 | Ended September 30, 2015 | 2014 |
| United States | \$ 2,245 | \$ 2,953 | \$10,726 | \$8,656 |
| International | 213 | 96 | 566 | 302 |
| Total Sales and Marketing | <u>\$ 2,458</u> | <u>\$ 3,049</u> | <u>\$11,292</u> | <u>\$8,958</u> |

Research and development expenses relate primarily to the development of new products to add to our portfolio and costs related to its medical affairs, medical information and regulatory functions. We do not allocate research and development expenses incurred in the United States to our International segment.

Total research and development expenses decreased \$0.6 million, or 19.4%, to \$2.5 million in the three months ended September 30, 2015, as compared to \$3.0 million in the three months ended September 30, 2014. In the U.S. segment, research and development expense decreased \$0.7 million, or 24.0%, to \$2.3 million in the three months ended September 30, 2015, as compared to \$3.0 million in the prior year period. In the International segment, research and development expense increased \$0.1 million, or 122.9%, to \$0.2 million in the three months ended September 30, 2015, as compared to \$0.1 million in the prior year period.

Total research and development expenses increased \$2.3 million, or 26.1%, to \$11.3 million in the nine months ended September 30, 2015, as compared to \$9.0 million in the nine months ended September 30, 2014. In the U.S. segment, research and development expense increased \$2.0 million, or 23.9%, to \$10.7 million in the nine months ended September 30, 2015, as compared to \$8.7 million in the prior year period. In the International segment, research and development expense increased \$0.3 million, or 87.4%, to \$0.6 million in the nine months ended September 30, 2015, as compared to \$0.3 million in the prior year period.

[Table of Contents](#)

The decrease in the U.S. segment research and development expenses for the three months ended September 30, 2015 over the prior year period is primarily due to a reduction in overhead costs associated with the decommissioning of certain long-lived assets and lower headcount.

The increase in the U.S. segment research and development expenses for the nine months ended September 30, 2015 over the prior year period is primarily due to an increase of \$3.4 million of depreciation expense as a result of the scheduled decommissioning of certain long-lived assets associated with R&D operations, a gain in the prior year associated with the sale of certain long-lived assets and change in headcount, offset by a reduction in overhead costs associated with the decommissioning of certain long-lived assets.

The increase in the International segment research and development expenses for the three and nine months ended September 30, 2015 over the prior year period is primarily due to increased regulatory costs.

Other Expense, Net

| (dollars in thousands) | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--------------------------------|-------------------------------------|-------------------|------------------------------------|-------------------|
| | 2015 | 2014 | 2015 | 2014 |
| Interest expense | \$(7,105) | \$(10,592) | \$(31,617) | \$(31,724) |
| Interest income | 5 | 7 | 18 | 20 |
| Loss on extinguishment of debt | — | — | (15,528) | — |
| Other income (expense), net | (183) | 441 | 234 | (148) |
| Total other expense, net | <u>\$(7,283)</u> | <u>\$(10,144)</u> | <u>\$(46,893)</u> | <u>\$(31,852)</u> |

Interest Expense

For the three months ended September 30, 2015, compared to the same period in 2014, interest expense decreased by \$3.5 million due to the refinancing of long-term debt. For the nine months ended September 30, 2015, compared to the same period in 2014, interest expense decreased by \$0.1 million due to the refinancing of long-term debt offset by a \$3.3 million interest payment made for interest through the redemption date (July 30, 2015) on the Senior Notes.

Interest Income

For the three and nine months ended September 30, 2015, compared to the same periods in 2014, interest income remained consistent.

Extinguishment of Debt

For the nine months ended September 30, 2015, we incurred a \$15.5 million loss on extinguishment of debt related to the redemption of LMI's Notes.

Other Income (Expense), net

For the three months ended September 30, 2015, compared to the same period in 2014, other expense increased by \$0.6 million as a result of an increase in foreign currency losses. For the nine months ended September 30, 2015, compared to the same period in 2014, other income increased by \$0.4 million as a result of a \$1.1 million increase in tax indemnification income as a result of settlement of state tax audits offset by a \$0.7 million increase in foreign currency losses.

Provision (Benefit) for Income Taxes

| (dollars in thousands) | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--------------------------------------|-------------------------------------|---------|------------------------------------|----------|
| | 2015 | 2014 | 2015 | 2014 |
| Provision (benefit) for income taxes | \$ 739 | \$ (56) | \$ 1,911 | \$ (374) |

For the nine months ended September 30, 2015 and 2014, our effective tax rate was 11.4% and 20.2%, respectively. The \$2.3 million decrease in the tax benefit for the nine months ended September 30, 2015, as compared to the same period in 2014, was impacted primarily by interest and penalties associated with uncertain tax positions, and the decrease in the valuation allowance from losses that cannot be benefitted. Considering our history of losses, we continue to maintain a valuation allowance against substantially all of our net deferred tax assets. Our provision (benefit) for income taxes results primarily from reversals of uncertain tax positions as

[Table of Contents](#)

statutes lapse or are settled during the year, offset by taxes due in certain foreign jurisdictions where we generate taxable income, as well as interest and penalties associated with uncertain tax positions. The following items had the most significant impact on the difference between our statutory U.S. federal income tax rate of 35% and our effective tax rate during the years ended:

Three months ended September 30, 2015

- A \$0.7 million increase in our uncertain tax positions relating to state tax nexus.
- A \$2.3 million decrease in the valuation allowance.

Nine months ended September 30, 2015

- A \$2.5 million increase in our uncertain tax positions relating to state tax nexus.
- A \$0.7 million decrease in our uncertain tax positions relating to a state tax settlement.
- A \$5.4 million increase in the valuation allowance for losses that are not benefitted.

Three months ended September 30, 2014

- A \$0.9 million increase in our uncertain tax positions primarily relating to the closing of a statute of limitations relating to transfer pricing matters.
- A \$0.7 million increase in our uncertain tax positions relating to accrued interest associated with state tax nexus and transfer pricing matters.
- A \$0.4 million increase relating to loss corporations with full valuation allowances for which the losses are not benefitted.

Nine months ended September 30, 2014

- A \$0.9 million decrease in our uncertain tax position primarily relating to the closing of a statute of limitations relating to a transfer pricing matters.
- A \$2.1 million increase in our uncertain tax positions relating to accrued interest associated with state tax nexus and transfer pricing matters.
- A \$1.8 million decrease in our uncertain tax positions relating to the New York State settlement agreement.
- A \$1.1 million increase relating to loss corporations with full valuation allowances for which the losses are not benefitted.

Liquidity and Capital Resources

Cash Flows

The following table provides information regarding our cash flows:

| <u>(dollars in thousands)</u> | <u>Nine Months Ended September 30,</u> | | |
|-------------------------------|--|-------------|------------------|
| | <u>2015</u> | <u>2014</u> | <u>\$ Change</u> |
| Cash provided by (used in): | | | |
| Operating activities | \$ 9,136 | \$15,465 | \$ (6,329) |
| Investing activities | \$(8,419) | \$ (4,848) | \$ (3,571) |
| Financing activities | \$ 2,041 | \$ (1,936) | \$ 3,977 |

Net Cash Provided by Operating Activities

Cash used in operating activities is primarily driven by our earnings and changes in working capital. The decrease in cash provided by operating activities for the nine months ended September 30, 2015 as compared to 2014 was primarily driven by decreases in cash flows in accrued expenses and other liabilities due to the timing of interest payments on long-term debt and cash flow decreases in inventory due to the timing of inventory receipts. Offsetting these decreases were increases in cash flows from accounts receivable due to improved cash collections and an increase in earnings, adjusted for non-cash items, primarily, non-cash write-offs and depreciation.

[Table of Contents](#)

Net Cash Used in Investing Activities

The increase in net cash used in investing activities in the nine months ended September 30, 2015 as compared to 2014 primarily reflects increased spending on the purchase of property and equipment.

Net Cash Provided by (Used in) Financing Activities

During the nine months ended September 30, 2015, we generated \$421.4 million from the net proceeds of the Term Facility together with the net proceeds from the IPO. The net proceeds generated from the Term Facility and the IPO were used to repay in full the aggregate principal amount of the \$400.0 million Notes, pay related premiums and expenses and pay down the \$8.0 million of outstanding borrowings under the Revolving Facility, which totaled \$417.8 million.

During the nine months ended September 30, 2014, we used cash from financing activities due to the cash use of \$1.8 million for offering costs.

External Sources of Liquidity

On June 30, 2015, we completed our IPO, entered into a new \$365.0 million seven-year Term Facility and amended and restated our Revolving Facility that has a borrowing capacity of \$50.0 million. The net proceeds of the Term Facility and the IPO together with available cash were used to repay in full the aggregate principal amount of the \$400.0 million Notes, and pay related premiums, interest and expenses and pay down \$8.0 million of borrowings under the Revolving Facility.

We have the right to request an increase of the Term Facility in an aggregate amount up to \$37.5 million plus additional amounts subject to certain leverage ratios. The term loans under the Term Facility bear interest, with pricing based from time to time at our election at (i) LIBOR plus a spread of 6.00% (with a LIBOR rate floor of 1.00%) or (ii) the Base Rate (as defined in our Term Facility) plus a spread of 5.00%. Interest under term loans based on (i) the LIBOR rate is payable at the end of each interest period (as defined in our Term Facility) and (ii) the Base Rate is payable at the end of each quarter.

The loans under our Revolving Facility bear interest subject to a pricing grid based on average historical excess availability, with pricing based from time to time at our election at (i) LIBOR plus a spread of 2.00% or (ii) the Reference Rate (as defined in our Revolving Facility) plus a spread of 1.00%. Our Revolving Facility also includes an unused line fee of 0.375% and expires on June 30, 2020.

As of September 30, 2015 and December 31, 2014, we had an unfunded Standby Letter of Credit for up to \$8.8 million. The unfunded Standby Letter of Credit requires annual fees, payable quarterly, which, subsequent to the amendment, is set at LIBOR plus a spread of 2.00% and expires on February 5, 2016, which will automatically renew for a one year period at each anniversary date, unless we elect not to renew in writing within 60 days prior to such expiration.

Our Revolving Facility is secured by a pledge of substantially all of the assets of LMI, together with the assets of the Company and assets of Lantheus Real Estate, including each such entity's accounts receivable, inventory and machinery and equipment, and is guaranteed by each of the Company and Lantheus Real Estate. Borrowing capacity is determined by reference to a borrowing base, or the Borrowing Base, which is based on (i) a percentage of certain eligible accounts receivable, inventory and machinery and equipment minus (ii) any reserves. As of September 30, 2015, the aggregate Borrowing Base was approximately \$46.2 million, which was reduced by an outstanding \$8.8 million unfunded Standby Letter of Credit and \$0.1 million in accrued interest resulting in a net borrowing base availability of approximately \$37.3 million. Our new Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the Revolving Facility may affect our ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage, accordingly, we may be limited in utilizing our net Borrowing Base availability as a source of liquidity.

Our Revolving Facility contains affirmative and negative covenants, as well as restrictions on the ability of LMI, us and our subsidiaries to: (i) incur additional indebtedness or issue preferred stock; (ii) repay subordinated indebtedness prior to its stated maturity; (iii) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (iv) make certain investments; (v) sell certain assets; (vi) create liens; (vii) consolidate, merge, sell or otherwise dispose of all or substantially all of our assets; and (viii) enter into certain transactions with our affiliates. Our Revolving Facility also contains customary default provisions as well as cash dominion provisions which allow the lender to sweep our accounts during the period (x) certain specified events of default are continuing under our Revolving Facility or (y) excess availability under our Revolving Facility falls below certain specific levels. During a covenant trigger period, we are required to comply with a consolidated fixed charge coverage ratio of not less than 1:00:1:00. The fixed charge coverage ratio is calculated on a consolidated basis for us on a trailing four-fiscal quarter period basis, as (i) EBITDA (as defined in the agreement) minus capital expenditures minus certain restricted payments divided by (ii) interest plus taxes paid or payable in cash plus certain restricted payments made in cash plus scheduled principal payments paid or payable in cash.

[Table of Contents](#)

Our Term Facility is guaranteed by the Company and Lantheus Real Estate, and obligations under the Term Facility are secured by substantially all the property and assets and all interests of the Company, LMI and Lantheus Real Estate.

Our Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Our Term Facility requires us to be in quarterly compliance, measured on a trailing four quarter basis. The financial covenants are displayed in the table below:

Term Facility Financial Covenants

| <u>Period</u> | <u>Total Net Leverage Ratio</u> |
|--------------------|---------------------------------|
| Q3 2015 to Q1 2016 | 6.25 to 1.00 |
| Q2 2016 to Q4 2016 | 6.00 to 1.00 |
| Q1 2017 to Q2 2017 | 5.50 to 1.00 |
| Thereafter | 5.00 to 1.00 |

The Term Facility contains usual and customary restrictions on the ability of us and our subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all or substantially all of our assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with our affiliates.

Our ability to fund our future capital needs will be affected by our ability to continue to generate cash from operations and may be affected by our ability to access the capital markets, money markets, or other sources of funding, as well as the capacity and terms of our financing arrangements.

We may from time to time repay our debt and take other steps to reduce our debt or otherwise improve our balance sheet. These actions may include prepayments of our term loan. The amount of debt that may be prepaid, if any, would be decided at the sole discretion of our Board of Directors and will depend on market conditions, trading levels of our debt from time to time, our cash position and other considerations.

Funding Requirements

Our future capital requirements will depend on many factors, including:

- our ability to have product manufactured and released from JHS and other manufacturing sites in a timely manner in the future;
- the pricing environment and the level of product sales of our currently marketed products, particularly DEFINITY and Xenon, and any additional products that we may market in the future;
- revenue mix shifts and associated volume and selling price changes that could result from contractual status changes with key customers;
- the costs of further commercialization of our existing products, particularly in international markets, including product marketing, sales and distribution and whether we obtain local partners to help share such commercialization costs;
- the costs of investing in our facilities, equipment and technology infrastructure;
- the costs and timing of establishing manufacturing and supply arrangements for commercial supplies of our products;
- the extent to which we acquire or invest in products, businesses and technologies;
- the extent to which we choose to establish collaboration, co-promotion, distribution or other similar arrangements for our marketed products;
- the legal costs relating to maintaining, expanding and enforcing our intellectual property portfolio, pursuing insurance or other claims and defending against product liability, regulatory compliance or other claims; and
- the cost of interest on any additional borrowings which we may incur under our financing arrangements.

[Table of Contents](#)

Until we successfully become dual sourced for our principal products, we are vulnerable to future supply shortages. Disruption in the financial performance could also occur if we experience significant adverse changes in customer mix, broad economic downturns, adverse industry or company conditions or catastrophic external events. If we experience one or more of these events in the future, we may be required to implement additional expense reductions, such as a delay or elimination of discretionary spending in all functional areas, as well as scaling back select operating and strategic initiatives.

If our capital resources become insufficient to meet our future capital requirements, we would need to finance our cash needs through additional public or private equity offerings, assets securitizations, debt financings, sale-leasebacks or other financing or strategic alternatives, to the extent such transactions are permissible under the covenants of our Revolving Facility and Term Facility. Additional equity or debt financing, or other transactions, may not be available on acceptable terms, if at all. If any of these transactions require an amendment or waiver under the covenants in our Revolving Facility and our Term Facility, which could result in additional expenses associated with obtaining the amendment or waiver, we will seek to obtain such a waiver to remain in compliance with the covenants of our Revolving Facility and Term Facility. However, we cannot be assured that such an amendment or waiver would be granted, or that additional capital will be available on acceptable terms, if at all.

At September 30, 2015, our only current committed external source of funds is our borrowing availability under our Revolving Facility. We had \$21.9 million of cash and cash equivalents at September 30, 2015. Availability under our Revolving Facility is calculated by reference to the Borrowing Base. If we are not successful in achieving our forecasted results, our accounts receivable and inventory could be negatively affected, reducing the Borrowing Base and limiting our borrowing availability. Our new Term Facility contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. Incremental borrowings under the revolving line of credit may affect our ability to comply with the covenants in the Term Facility, including the financial covenant restricting total net leverage, accordingly, we may be limited in utilizing our net Borrowing Base availability as a source of liquidity.

Based on our current operating plans, we believe that our existing cash and cash equivalents, results of operations and availability under our Revolving Facility will be sufficient to continue to fund our liquidity requirements for at least the next twelve months.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial position and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition and related allowances, inventory, impairments of long-lived assets including intangible assets, impairments of goodwill, income taxes including the valuation allowance for deferred tax assets.

There have been no material changes to our critical accounting policies or in the underlying accounting assumptions and estimates used in such policies in the nine months ended September 30, 2015. For further information, refer to our summary of significant accounting policies and estimates in our Prospectus.

Off-Balance Sheet Arrangements

We are required to provide the U.S. Nuclear Regulatory Commission, or NRC, and Massachusetts Department of Public Health financial assurance demonstrating our ability to fund the decommissioning of our North Billerica, Massachusetts production facility upon closure, though we do not intend to close the facility. We have provided this financial assurance in the form of a \$28.2 million surety bond and an \$8.8 million letter of credit.

Since inception, we have not engaged in any other off-balance sheet arrangements, including structured finance, special purpose entities or variable interest entities.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk from changes in interest rates and foreign currency exchange rates. We do not hold or issue financial instruments to reduce these risks or for trading purposes.

[Table of Contents](#)**Interest Rate Risk**

As a result of our new Term Facility, we have substantial variable rate debt. Fluctuations in interest rates may affect our business, financial condition, results of operations and cash flows. As of September 30, 2015, we had \$364.1 million outstanding under our Term Facility with a variable interest rate that only varies to the extent LIBOR exceeds one percent.

Furthermore, we are subject to interest rate risk in connection with the Revolving Facility, which is variable rate indebtedness. Interest rate changes could increase the amount of our interest payments and thus negatively impact our future earnings and cash flows. As of September 30, 2015, there was an \$8.8 million unfunded Standby Letter of Credit and \$0.1 million accrued interest, which reduced availability to \$37.3 million on the Revolving Facility. Any increase in the interest rate under the Revolving Facility may have a negative impact on our future earnings to the extent we have outstanding borrowings under the Revolving Facility. The effect of a 100 basis points adverse change in market interest rates, in excess of minimum floors, on our interest expense would be approximately \$966,000.

Historically, we have not used derivative financial instruments or other financial instruments to hedge such economic exposures.

Foreign Currency Risk

We face exposure to movements in foreign currency exchange rates whenever we, or any of our subsidiaries, enter into transactions with third parties that are denominated in currencies other than ours, or its, functional currency. Intercompany transactions between entities that use different functional currencies also expose us to foreign currency risk. During the nine months ended September 30, 2015 and 2014, the net impact of foreign currency changes on transactions was a loss of \$1.0 million and \$0.3 million, respectively. Historically, we have not used derivative financial instruments or other financial instruments to hedge such economic exposures.

Gross margins of products we manufacture at our U.S. plants and sell in currencies other than the U.S. Dollar are also affected by foreign currency exchange rate movements. Our gross margin on revenues for the nine month periods ended September 30, 2015 and 2014 was 46.0% and 41.3%, respectively. If the U.S. Dollar had been stronger by 1%, 5% or 10%, compared to the actual rates during the nine months ended September 30, 2015, we estimate our gross margin on revenues would have increased by 0.1%, 0.3% and 0.7%, respectively. If the U.S. Dollar had been stronger by 1%, 5% or 10%, compared to the actual rates during the nine months ended September 30, 2014, we estimate our gross margin on revenues would have increased by 0.0%, 0.2% and 0.5%, respectively.

In addition, a portion of our earnings is generated by our foreign subsidiaries, whose functional currencies are other than the U.S. Dollar. Our earnings could be materially impacted by movements in foreign currency exchange rates upon the translation of the earnings of those subsidiaries into the U.S. Dollar. The Canadian Dollar presents the primary currency risk on our earnings.

If the U.S. Dollar had been uniformly stronger by 1%, 5% or 10%, compared to the actual average exchange rates used to translate the financial results of our foreign subsidiaries, our revenues and net income for the nine months ended September 30, 2015 would have been impacted by approximately the following amounts:

| <u>Increase in U.S. Dollar to Applicable Foreign Currency Exchange Rate</u> | <u>Approximate Decrease in Revenues</u> | <u>Approximate Decrease in Net Loss</u> |
|---|---|---|
| | (dollars in thousands) | |
| 1% | \$ (290) | \$ (64) |
| 5% | (1,449) | (320) |
| 10% | (2,899) | (640) |

If the U.S. Dollar had been uniformly stronger by 1%, 5% or 10%, compared to the actual average exchange rates used to translate the financial results of our foreign subsidiaries, our revenues and net loss for the nine months ended September 30, 2014 would have been impacted by approximately the following amounts:

| <u>Increase in U.S. Dollar to Applicable Foreign Currency Exchange Rate</u> | <u>Approximate Decrease in Revenues</u> | <u>Approximate Decrease in Net Loss</u> |
|---|---|---|
| | (dollars in thousands) | |
| 1% | \$ (332) | \$ (16) |
| 5% | (1,658) | (79) |
| 10% | (3,316) | (157) |

[Table of Contents](#)

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) or 15d-15(e) promulgated under the Exchange Act. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control Over Financial Reporting

There have been no changes during the quarter ended September 30, 2015 in our internal control over financial reporting (as defined in Rule 13a-15(f) promulgated under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we are a party to various legal proceedings arising in the ordinary course of business. In addition, we have in the past been, and may in the future be, subject to investigations by governmental and regulatory authorities which exposes us to greater risks associated with litigation, regulatory or other proceedings, as a result of which we could be required to pay significant fines or penalties. The outcome of litigation, regulatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to us. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against us, could materially and adversely affect our financial condition or results of operations.

On December 16, 2010, we filed suit against one of our insurance carriers seeking to recover business interruption losses associated with the NRU reactor shutdown and the ensuing global Moly supply shortage (Lantheus Medical Imaging, Inc., Plaintiff v. Zurich American Insurance Company, Defendant, United States District Court, Southern District of New York, Case No. 10 Civ 9371). The claim is the result of the shutdown of the NRU reactor in Chalk River, Ontario. The NRU reactor was off-line from May 2009 until August 2010. The defendant answered the complaint on January 21, 2011, denying substantially all of the allegations, presenting certain defenses and requesting dismissal of the case with costs and disbursements. Discovery, including international discovery and related motion practice, went on for more than three years. The defendant filed a motion for summary judgment on July 14, 2014. The Company filed a memorandum of law in opposition to defendant's motion for summary judgment on August 25, 2014. The defendant filed a reply memorandum of law in further support of its motion for summary judgment on September 15, 2014. Expert witness discovery was completed on October 31, 2014. On March 25, 2015, the United States District Court for the Southern District of New York granted defendant's motion for summary judgment. On September 4, 2015, we filed an appeal of the District Court decision with the United States Court of Appeals for the Second Circuit. We cannot be certain when, if ever, we will be able to recover for business interruption losses related to this matter and in what amount, if any.

Except as noted above, as of September 30, 2015, we had no material ongoing litigation, regulatory or other proceeding and had no knowledge of any investigations by governmental or regulatory authorities in which we are a target that could have a material adverse effect on our current business.

Item 1A. Risk Factors

There have been no material changes in the risk factors set forth in our Prospectus except as set forth below. For further information, refer to "Risk Factors" in our Prospectus.

We face significant competition in our business and may not be able to compete effectively.

The market for diagnostic medical imaging agents is highly competitive and continually evolving. Our principal competitors in existing diagnostic modalities include large, global companies with substantial financial, manufacturing, sales and marketing and logistics resources that are more diversified than ours, such as GE Healthcare, Bracco Diagnostics Inc., or Bracco, Mallinckrodt, Bayer Schering Pharma AG, or Bayer, and DRAXIS Specialty Pharmaceuticals Inc. (an affiliate of JHS), or Draxis, as well as other competitors. We cannot anticipate their actions in the same or competing diagnostic modalities, such as significant price reductions on products that are comparable to our own, development or introduction of new products that are more cost-effective or have superior performance than our current products, the introduction of generic versions when our proprietary products lose their patent protection or the new entry into a generic market in which we are already a participant. In addition, distributors of our products could attempt to

[Table of Contents](#)

shift end-users to competing diagnostic modalities and products. Our current or future products could be rendered obsolete or uneconomical as a result of these activities. Our failure to compete effectively could cause us to lose market share to our competitors and have a material adverse effect on our business, results of operations, financial condition and cash flows.

In October 2014, Bracco received FDA approval in the United States for its echocardiography agent, Lumason (known as SonoVue outside of the U.S.), which is already approved for sale in Europe and certain Asian markets, including China, Japan and Korea. Bracco now has one of three FDA-approved echocardiography contrast agents in the United States, together with GE Healthcare's Optison and our DEFINITY. Bracco formally launched Lumason in the United States on April 27, 2015. If Bracco successfully commercializes Lumason in the United States without otherwise increasing the overall usage of ultrasound contrast agents, our current and future sales volume could suffer, which would have a material adverse effect on our business, results of operations, financial condition and cash flows.

Xenon for lung ventilation diagnosis is our third largest product by revenue. Historically, several companies sold packaged Xenon as a pulmonary imaging agent in the U.S., but since 2010 we have been the only supplier of this imaging agent in the U.S. We understand that a radiopharmaceutical manufacturer is now seeking regulatory approval from the FDA to sell packaged Xenon in the U.S. If that manufacturer receives FDA approval and begins to sell packaged Xenon in the U.S., depending upon the pricing, extent of availability and market penetration of the new offering, we believe we could experience substantial volume loss and price erosion with existing Xenon customers who are not subject to price or volume commitments, such as Cardinal Health, historically our largest Xenon customer. Although we intend to compete vigorously in the market for this important imaging agent, we believe that these developments could have a material adverse effect on our business, results of operations, financial condition and cash flows.

We face potential supply and demand challenges for Xenon.

Currently, Nordion is our sole supplier, and we believe the principal supplier on a global basis, of Xenon, which is captured by the NRU reactor as a by-product of the Moly production process. In January 2015, we entered into a new strategic agreement with IRE for the future supply of Xenon. Under the terms of the agreement, IRE will provide bulk Xenon to us for processing and finishing once development work has been completed and all necessary regulatory approvals have been obtained. We currently estimate commercial production will occur in 2016. If we are not able to begin providing commercial quantities of Xenon prior to the NRU reactor's transition in October 2016 from providing regular supply of medical isotopes to providing only emergency back-up supply of medical isotopes through March 2018, there may be a period of time during which we are not able to offer Xenon in our portfolio of commercial products, which would have a negative effect on our business, results of operations, financial condition and cash flows. For the year ended December 31, 2014, Xenon represented approximately 12% of our revenues.

Currently, we obtain Xenon from Nordion on a purchase order basis. If we are not able to pass along to our customers any change of terms from our supplier, there could be a negative effect on our business, results of operations, financial condition and cash flows.

Currently, we are the only supplier of packaged Xenon in the U.S., although historically several companies also sold packaged Xenon as a pulmonary imaging agent in the U.S. We understand that a radiopharmaceutical manufacturer is now seeking regulatory approval from the FDA to sell packaged Xenon in the U.S. If that manufacturer receives FDA approval and begins to sell packaged Xenon in the U.S., depending upon the pricing, extent of availability and market penetration of the new offering, we believe we could experience substantial volume loss and price erosion with existing Xenon customers who are not subject to price or volume commitments, such as Cardinal Health, historically our largest Xenon customer. Although we intend to compete vigorously in the market for this important imaging agent, we believe that these developments could have a material adverse effect on its business, results of operations, financial condition and cash flows.

In addition to a possible new supplier of packaged Xenon in the U.S., if there is an increase in the use of other imaging modalities in place of packaged Xenon, our current sales volumes would decrease, which could have a negative effect on our business, results of operations, financial condition and cash flows.

Xenon is frequently administered as part of a ventilation scan to evaluate pulmonary function prior to a perfusion scan with microaggregated albumin, or MAA, a technetium-based radiopharmaceutical used to evaluate blood flow to the lungs. Currently, Draxis is the sole supplier of MAA on a global basis. In 2014, Draxis announced substantial price increases for MAA. The increased price of MAA, or difficulties in obtaining MAA, could decrease the frequency in which MAA is used for lung perfusion evaluation, in turn, decreasing the frequency that Xenon is used for pulmonary function evaluation, resulting in a negative effect on our business, results of operations, financial condition and cash flows.

[Table of Contents](#)

If we lose the services of our key personnel, our business could be adversely affected.

Our success is substantially dependent upon the performance, contributions and expertise of our chief executive officer, executive leadership and senior management team. Mary Anne Heino, our Chief Executive Officer and President, and John Bakewell, our Chief Financial Officer, and other members of our executive leadership and senior management team play a significant role in generating new business and retaining existing customers. We have employment agreements with Ms. Heino and Mr. Bakewell and a limited number of other individuals on our executive leadership team, although we cannot prevent them from terminating their employment with us. We do not maintain key person life insurance policies on any of our executive officers. While we have experienced both voluntary and involuntary turnover on our executive leadership team, to date we have been able to attract new, qualified individuals to lead our company and key functional areas. All of the options granted to employees under our 2008 Equity Incentive Plan and 2013 Equity Incentive Plan are currently out-of-the-money, although we have also made restricted stock grants to employees under our 2013 Equity Incentive Plan and 2015 Equity Incentive Plan. Our inability to retain our existing executive leadership and senior management team, maintain an appropriate internal succession program or attract and retain additional qualified personnel could have a material adverse effect on our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Unregistered Sales of Equity Securities

None.

Initial Public Offering of Common Stock

On June 30, 2015, we completed an IPO of our common stock at a price to the public of \$6.00 per share. Our common stock is now traded on the NASDAQ Global Select Market (NASDAQ) under the symbol “LNTH”. We issued and sold 12,256,577 shares of common stock in the IPO, including 1,423,243 shares that were offered and sold pursuant to the underwriters’ exercise in full of its overallotment option. The IPO raised proceeds of approximately \$67.2 million, after deducting underwriting discounts, commissions and related expenses.

Repurchases

The following table presents information with respect to purchases of common stock we made during the quarter ending September 30, 2015. The Company does not have a share repurchase program in effect. The 2015 Equity Incentive Plan, or the 2015 Plan, provides for the withholding of shares to satisfy tax obligations. It does not specify a maximum number of shares that can be withheld for this purpose. The shares of common stock withheld to satisfy tax withholding obligations may be deemed to be “issuer purchases” of shares that are required to be disclosed pursuant to this Item.

| Period | Total Number of Shares Purchased | Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program |
|----------------|----------------------------------|------------------------------|---|--|
| July 2015 | 13,020 | \$ 7.47 | * | * |
| August 2015 | — | \$ — | * | * |
| September 2015 | — | \$ — | * | * |
| Total | 13,020 | \$ 7.47 | * | |

* These amounts are not applicable as the Company does not have a share repurchase program in effect.

Item 4. Mine Safety Disclosures

Not applicable.

[Table of Contents](#)

Item 6. Exhibits

| <u>EXHIBIT NUMBER</u> | <u>DESCRIPTION OF EXHIBITS</u> | <u>INCORPORATED BY REFERENCE</u> | | | |
|---------------------------|--|----------------------------------|------------------------|----------------|------------------------|
| | | <u>FORM</u> | <u>FILE NUMBER</u> | <u>EXHIBIT</u> | <u>FILING DATE</u> |
| 10.1* | Retirement and Consulting Agreement, dated August 27, 2015, by and between Lantheus Medical Imaging, Inc. and Jeffrey Bailey. | | | | |
| 10.2* | Amendment to Employment Agreement, dated August 31, 2015, by and between Lantheus Medical Imaging, Inc. and Mary Anne Heino. | | | | |
| 31.1* | Certification of the Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | | | |
| 31.2* | Certification of the Chief Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | | | |
| 32.1* | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002. | | | | |
| 101.INS* | XBRL Instance Document | | | | |
| 101.SCH* | XBRL Taxonomy Extension Schema Document | | | | |
| 101.CAL* | XBRL Taxonomy Extension Calculation Linkbase Document | | | | |
| 101.DEF* | XBRL Taxonomy Extension Definition Linkbase Document | | | | |
| 101.LAB* | XBRL Taxonomy Extension Label Linkbase Document | | | | |
| 101.PRE* | XBRL Taxonomy Extension Presentation Linkbase Document | | | | |

* Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LANTHEUS HOLDINGS, INC.

By: /s/ MARY ANNE HEINO
Name: Mary Anne Heino
Title: *President and Chief Executive Officer*
Date: November 4, 2015

LANTHEUS HOLDINGS, INC.

By: /s/ JOHN BAKEWELL
Name: John Bakewell
Title: *Chief Financial Officer*
Date: November 4, 2015

EXHIBIT INDEX

| <u>EXHIBIT NUMBER</u> | <u>DESCRIPTION OF EXHIBITS</u> | <u>INCORPORATED BY REFERENCE</u> | | | |
|----------------------------------|--|---|-------------------------------|-----------------------|-------------------------------|
| | | <u>FORM</u> | <u>FILE NUMBER</u> | <u>EXHIBIT</u> | <u>FILING DATE</u> |
| 10.1* | Retirement and Consulting Agreement, dated August 27, 2015, by and between Lantheus Medical Imaging, Inc. and Jeffrey Bailey. | | | | |
| 10.2* | Amendment to Employment Agreement, dated August 31, 2015, by and between Lantheus Medical Imaging, Inc. and Mary Anne Heino. | | | | |
| 31.1* | Certification of the Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | | | |
| 31.2* | Certification of the Chief Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | | | | |
| 32.1* | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002. | | | | |
| 101.INS* | XBRL Instance Document | | | | |
| 101.SCH* | XBRL Taxonomy Extension Schema Document | | | | |
| 101.CAL* | XBRL Taxonomy Extension Calculation Linkbase Document | | | | |
| 101.DEF* | XBRL Taxonomy Extension Definition Linkbase Document | | | | |
| 101.LAB* | XBRL Taxonomy Extension Label Linkbase Document | | | | |
| 101.PRE* | XBRL Taxonomy Extension Presentation Linkbase Document | | | | |

* Filed herewith

RETIREMENT AND CONSULTING AGREEMENT

THIS RETIREMENT AND CONSULTING AGREEMENT (“Agreement”) is made and entered into as of August 27, 2015, by and between Jeffrey Bailey (“Executive,” “You” or “Your”) and Lantheus Medical Imaging, Inc. (defined herein to include its affiliates, subsidiaries, parents, predecessors, successors and assigns, and hereinafter referred to as “Lantheus” or the “Company”) (together, the “Parties”).

RECITALS

WHEREAS, Your last date of employment with the Company shall be August 31, 2015 (the “Separation Date”);

WHEREAS, You and the Company are parties to an Employment Agreement, dated May 8, 2013 (as amended on June 25, 2015, the “Employment Agreement”);

WHEREAS, You and the Company wish to confirm the terms of Your separation from employment and to settle, release and discharge, with prejudice, any and all claims You have or may have against the Released Parties (defined in Section 4(a) below), including but not limited to those pertaining to or arising out of Your employment and/or Your separation from employment with the Company;

WHEREAS, the Company wishes and You agree to provide consulting services to the Company following Your separation from employment; and

WHEREAS, You and the Company have read this Agreement and have had the opportunity to review it with their respective legal counsel.

NOW, THEREFORE, in consideration of the promises and covenants contained herein, You and the Company understand and agree as follows:

1. **Separation of Employment.**

Your employment with the Company shall end as of Your Separation Date, and, in accordance with Section 4(i) of the Employment Agreement, You hereby resign from any and all Lantheus boards of directors, boards of trustees and/or executive or management committees and from any and all Lantheus offices effective as of Your Separation Date.

2. **Acknowledgment of Receipt of Accrued and Vested Pay and Benefits.**

(a) You acknowledge, upon signing this Agreement, that as of the Company’s most recent payroll date, You had been paid all Base Salary (as defined in the Employment Agreement) then payable to you up to such payroll date. The Company shall pay You, no later than the first regularly scheduled payroll date following Your Separation Date, (i) all accrued and unpaid Base Salary as of Your Separation Date, (ii) all reasonable business expenses reimbursable under Section 3(e) of the Employment Agreement, subject to satisfaction of any other requirements under applicable Company policies and (iii) any amount required under the Company’s vacation policy with respect to Your accrued and unused vacation days as of Your Separation Date. You acknowledge that You did not earn any Annual Cash Bonus (as defined in the Employment Agreement) pursuant to Section 3(c) of the Employment Agreement with respect to the fiscal year ending December 31, 2015 and that You are not entitled to be paid any bonus amount with respect to such fiscal year.

(b) The Company agrees that You shall be entitled to any accrued and vested health and fringe benefits due to You in accordance with the Company’s benefit plans (other than severance).

3. **Payments and Other Benefits to be Provided to You in Exchange for the Release and Your Obligations Under this Agreement**

(a) In exchange for and in consideration of Your covenants and promises set forth in this Agreement, contingent upon Your complying with and fulfilling in all material respects each and every one of Your obligations under this Agreement (including, but not limited to (i) the Company's receipt from You of a signed, effective and irrevocable original or PDF copy of this Agreement and (ii) Your reasonable cooperation in the reconciliation and closing of Your Company-issued Visa account to a zero dollar (\$0.00) balance), all of which are conditions precedent to any payment or other obligation on the part of the Company under this Section 3, Lantheus agrees to provide You with the following payments and other benefits on behalf of all Released Parties (defined in Section 4(a) below):

(i) The Company shall pay You an amount in cash equal to one third of Your Base Salary as of the Separation Date (\$183,333.33), which shall be paid in a lump sum on the first regularly scheduled payroll date following the Effective Date;

(ii) The Company shall pay the premiums for continuing medical, dental and vision coverage under the Consolidated Omnibus Budget Reconciliation Act (collectively, the "Health Benefits"); provided, that Your Health Benefits shall cease upon the earlier of (x) August 31, 2016 and (y) Your becoming employed by another employer and eligible for medical coverage, dental coverage and/or vision coverage, as applicable, with such other employer; and

(iii) the Company shall retain Your services as a consultant, on an as needed basis, following Your Separation Date (the "Consulting Period"). The Consulting Period shall continue for seven months after the Separation Date. You shall be compensated at a rate of \$100,000 per month during the Consulting Period (the "Consulting Pay"), with payments made at the same time the Company makes its regular payroll payments and with the first payment made on the next scheduled payroll date following the Effective Date. During the Consulting Period, You shall make Yourself available, as reasonably requested by the Company, for the orderly transition of Your responsibilities. You acknowledge and agree that, during the Consulting Period, (i) You will be an independent contractor, and not an employee of the Company within the meaning of all federal, state and local laws and regulations governing employment relationships, including insurance, workers' compensation, industrial accident, labor and taxes, as the economic reality of your relationship with the Company is one of an independent contractor rather than an employee; (ii) except as expressly authorized by the Company, You shall not have any right to act for, represent or otherwise bind the Company or any of its subsidiaries in any manner; (iii) in Your capacity as a consultant and subject to Section 3(a) (ii), You shall not be entitled to participate in any employee benefit plans or arrangements of the Company and shall not be provided with health and welfare benefits, including, without limitation, medical and dental coverage; (iv) You shall be solely responsible for any workers' compensation, unemployment or disability insurance payments, or any social security, income tax or other withholdings, deductions or payments (including self-employment taxes) that may be required by federal, state or local law with respect to any sums paid to You in Your capacity as a consultant; (v) You shall be required to pay and shall timely remit all self-employment taxes to the Internal Revenue Service and any other required governmental agencies; and (vi) the Company shall pay You in a manner consistent with your status as an independent contractor, including issuing You a Form 1099. To the extent that You incur business expenses in the performance of such services, You shall be entitled to reimbursement consistent with the standards and procedures applicable to business expense reimbursement for employees.

4. **Release of Claims and Cancellation of Incentive Equity.**

(a) In exchange for Lantheus providing You with the payments and other benefits set forth in Section 3, You, individually and on behalf of Your heirs, executors, personal representatives, administrators, agents and assigns, forever waive, release, give up and discharge all waivable claims, real or perceived, whether now known or unknown, against the Company, its parent, subsidiaries, and other related and affiliated companies, their employee benefit plans and trustees, fiduciaries, administrators, sponsors and parties-in-interest of those plans, and all of their past and present employees, managers, directors, officers, administrators, shareholders, members, agents, attorneys, insurers, re-insurers and contractors acting in any capacity whatsoever, and all of their respective predecessors, heirs, personal representatives, successors and assigns (collectively, the “Released Parties” as used throughout this Agreement), arising out of and in any way concerning Your employment with the Company, any terms, conditions or privileges related to Your employment with the Company, the termination of Your employment by the Company, and all alleged violations of federal, state or local fair employment practices or laws by any of the Released Parties for any reason and under any legal theory including, but not limited to, Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000(e), *et seq.* (“Title VII”), the Americans with Disabilities Act, 42 U.S.C. § 12101, *et seq.* (“ADA”), the Age Discrimination in Employment Act, 29 U.S.C. § 621, *et seq.* (“ADEA”), the Older Worker Benefits Protection Act, 29 U.S.C. § 626(f), *et seq.* (“OWBPA”), the Employee Retirement Income Security Act of 1974, as amended, 29 U.S.C. 1001, *et seq.* (“ERISA”), the Civil Rights Act of 1991, 42 U.S.C. §§ 1981, 1983, 1985, 1986 and 1988, the Family and Medical Leave Act, 29 U.S.C. § 2601, *et seq.* (“FMLA”), the Equal Pay Act of 1963, 29 U.S.C. § 206, *et seq.* (“EPA”), the Lilly Ledbetter Fair Pay Act of 2009, H.R. 11 (“Fair Pay Act”), the Consolidated Omnibus Budget Reconciliation Act, 29 U.S.C. § 1161, *et seq.* (“COBRA”), the Occupational Safety and Health Act, 29 U.S.C. 651 *et seq.* (“OSHA”), the New York State Civil Rights Law, N.Y. Exec. Law § 291, *et seq.*, the New York State Human Rights Law, N.Y. Exec. Law § 296(1) (a), *et seq.*, the New York City Civil Rights Law, N.Y.C. Admin. Code § 8-102(5), *et seq.*, the New York State Wage Payment Law, N.Y. Lab. Law § 190(1), *et seq.*, the New York State Whistleblower Law, N.Y. Lab. Law § 740, *et seq.*, the Massachusetts Fair Employment Practices Act, Mass. Gen. Laws ch. 151B, §§ 1 to 10; the common law of the States of Massachusetts and New York; and all other federal or state or local laws, regulations, rules, ordinances, or orders, as they may be amended. You also forever waive, release, discharge and give up all claims, real or perceived and now known or unknown, for breach of implied or express contract, including but not limited to breach of promise, breach of the covenant of good faith and fair dealing, misrepresentation, negligence, fraud, estoppel, defamation, libel, misrepresentation, intentional infliction of emotional distress, violation of public policy, wrongful, retaliatory or constructive discharge, assault, battery, false imprisonment, negligence, and all other claims or torts arising under any federal, state, or local law, regulation, ordinance or judicial decision, or under the United States, New York and Massachusetts Constitutions. You have agreed to and do waive any and all claims You may have for employment or reinstatement by the Company or any of the Released Parties and have agreed not to seek such employment or reemployment by the Company or any of the Released Parties in the future.

(b) The Company and You acknowledge and agree that the release contained in Section 4(a) does not, and shall not be construed to, release or limit the scope of any existing obligation of the Company and/or any of its subsidiaries or affiliates to (i) indemnify You for Your acts as an officer or director of the Company in accordance with the bylaws of the Company or the law or (ii) You and Your eligible, participating dependents or beneficiaries under any existing group welfare (excluding severance), equity, or retirement plan of the Company in which You and/or such dependents are participants. In addition, nothing in this Agreement shall be construed to limit Your entitlement to insurance coverage as a former director and/or officer under the Company’s liability insurance policy with respect to directors and officers (“D&O Insurance”). The Company shall ensure that it maintains D&O Insurance coverage for You with respect to any claims related to Your activities on behalf of the Company that may be brought against You at any time within the period of any applicable statute of limitations.

(c) In exchange for Lantheus providing You with the payments and other benefits set forth in Section 3, You further agree that (i) the Restricted Stock Award Agreement between You and Lantheus Holdings, Inc., the indirect parent entity of the Company ("Holdings"), dated as of April 6, 2015, shall be terminated and void ab initio as of Your Separation Date, and all shares of restricted common stock awarded thereunder shall be cancelled and extinguished in all respects with no further rights in respect thereof, and (ii) the options granted to You under the Option Grant Award Agreement, made as of May 8, 2013, between Holdings and You, shall be cancelled and expired in all respects with no further rights in respect thereof.

(d) Notwithstanding the release contained in Section 4(a) above, You do not waive: (i) Your right to bring an action to enforce the terms of this Agreement; (ii) Your rights with respect to the capital stock of Holdings that You own and all rights with respect thereto under the Amended and Restated Shareholders Agreement, dated as of February 26, 2008, among Holdings and certain other parties thereto, as amended; or (iii) Your right to file a charge with the EEOC or participate in an investigation conducted by the EEOC; however, You expressly waive Your right to monetary or other relief should any administrative agency, including but not limited to the EEOC, pursue any claim on Your behalf.

5. **Covenant Not to Sue.**

You warrant that You do not have any complaint, charge or grievance against any Released Party pending before any federal, state or local court or administrative or arbitral agency, and You further agree and covenant not to sue, file a lawsuit, or commence any other proceeding, arbitral, administrative or judicial, against any of the Released Parties in any court of law or equity, or before any arbitral body or administrative agency, with respect to any matter arising from or relating to Your employment with the Released Parties, Your separation thereof, or otherwise (including, for the avoidance of doubt, any matter released in Section 4(a) above), provided, however, that this covenant not to sue does not affect Your rights to enforce appropriately the terms of this Agreement in a court of competent jurisdiction and does not affect Your right to file a charge with the EEOC or participate in an investigation conducted by the EEOC; however, You expressly waive Your right to monetary or other relief should any administrative agency, including but not limited to the EEOC, pursue any claim on Your behalf. Should You file a lawsuit with any court or arbitration panel concerning any claim, demand, issue, or cause of action waived through this Agreement, You agree that You will be responsible to pay the legal fees and costs that the Released Parties incur defending that lawsuit. Further, You agree that nothing in this Agreement shall limit the right of a court to determine, in its sole discretion, that the Released Parties are entitled to restitution, recoupment or set off of any monies paid should the release of any claims under this Agreement subsequently be found to be invalid.

6. **Non-Admission of Liability.**

You agree that this Agreement shall not in any way be construed as an admission that any of the Released Parties owe You any money or have acted wrongfully, unlawfully, or unfairly in any way towards You. In fact, You understand that the Released Parties specifically deny that they have violated any federal, state or local law or ordinance or any right or obligation that they owe or might have owed to You at any time, and maintain that they have at all times treated You in a fair, non-discriminatory and non-retaliatory manner. Further, you affirm that you are not aware of any wrongdoing, regulatory violations or corporate fraud committed by the Company or its employees that has not otherwise been previously reported to the Company in writing. The Company agrees that this Agreement shall not in any way be construed as an admission that You have acted wrongfully, unlawfully, or unfairly in any way

towards the Company or any of the Released Parties. In fact, the Company understands that You specifically deny that You have violated any federal, state or local law or ordinance or any right or obligation that You owe or might have owed to the Company or any of the Released Parties at any time.

7. **Reference-Related Communications.**

You agree that, should You or any prospective employer for You desire that Lantheus engage in any reference-related communications, You will direct such inquiries exclusively to Michael Duffy, the General Counsel of the Company, for confirmation only of Your: (a) dates of employment; (b) employment position; (c) base salary; and (d) as applicable, bonuses or incentive compensation pay. You also agree that, except for the Company's verbal confirmation of dates of employment, position title, base salary and, as applicable, bonuses or incentive compensation pay as expressly set forth above, the Released Parties will have no obligation to engage in any reference-related communications whatsoever with Your past, existing or prospective employers unless compelled by a court order or other legal process. Notwithstanding the foregoing, You may also direct reference-related inquiries to Brian Markison. Mr. Markison shall have no obligation to respond to any such inquiries that You direct to him, but if, in his discretion, he elects to do so, You expressly covenant not to sue or otherwise initiate any action or proceeding pertaining to or arising out of any reference-related communications by Mr. Markison.

8. **Cooperation.**

(a) In accordance with Section 9 of the Employment Agreement, You agree to cooperate fully and in good faith with the Company and its legal counsel as may be necessary to respond to any inquiries that may arise with respect to matters that You were responsible for or involved with during Your employment with Lantheus.

(b) You agree to cooperate fully and in good faith with the Company and its legal counsel in connection with any defense, prosecution or investigation of any and all actual, threatened, potential or pending court or administrative proceedings or other legal matters in which You may be involved as a party and/or in which the Company determines, in its sole discretion, reasonably exercised, that You are a relevant witness or have relevant knowledge or information. In connection with such matters, You agree to notify, communicate and be represented by counsel of the Company's choosing, to fully cooperate and work with such counsel with respect to, and in preparation for, any depositions, interviews, responses, appearances, or other legal matters, and to testify honestly with respect to all matters. You shall also be entitled to appoint, at Your request, Your own legal counsel in addition to the Company's counsel in connection with any legal matters covered by this Section 8; provided, that, unless such legal matters relate to claims for which You are seeking indemnification, in which case the relevant insurance policy or other document, agreement or instrument governing Your right to seek indemnification shall apply, the Company will pay the reasonable and documented expenses of Your own legal counsel if Lantheus determines, in its sole discretion, reasonably exercised, that Your interests are adverse to or in conflict with those of the Company and/or that providing counsel to You would be a conflict of interest. The selection by You of Your own counsel shall in no way detract from or interfere with any of the obligations You have to cooperate with the Company as agreed to herein.

(c) If the Company seeks Your cooperation under this Section 8 or under Section 9 of the Employment Agreement, it shall reimburse You for any reasonable out of pocket expenses You incur in connection with such cooperation, provided that You timely submit valid receipts for reimbursement to the Company. You shall not be required to perform a total of more than 80 hours of cooperation services after Your obligation to perform consulting services under Section 3(a)(iii) ends.

(d) Your cooperation will include providing Lantheus with written notice of any subpoena or other compulsory process served upon You within forty-eight (48) hours of its occurrence, meeting with the Company's attorneys, providing the attorneys with requested information, and working with the attorneys in preparation for Your involuntary appearance. In connection with such matters, You agree to fully cooperate and work with the Company's counsel with respect to, and in preparation for, any response to a subpoena or other compulsory process served upon You, and to testify honestly with respect to all matters.

(e) In no event shall the Company have any obligation to provide counsel to You in connection with any legal matters or litigation which may arise between You and the Company, if any.

9. **Non-Disparagement**

You acknowledge Your continuing obligations in accordance with Section 5(d) of the Employment Agreement. You affirm that You have complied with this provision, and You agree that You will continue to abide by the terms and conditions of Section 5(d) of the Employment Agreement. For its part, the Company acknowledges its obligations under Section 5(d) of the Employment Agreement and affirms that it has complied with this provision, and agrees that it will continue to abide by the terms and conditions of Section 5(d) of the Employment Agreement. Each Party further acknowledges that, as of the date hereof, he or it has no knowledge or information to indicate that the other Party has violated Section 5(d) of the Employment Agreement and each agrees that no statement by the other Party that it is aware of and that is in the public domain as of the original date of the proposal of this Agreement (i.e., August 20, 2015) constitutes a violation of Section 5(d) of the Employment Agreement.

10. **Non Disclosure of Confidential Information and Return of Company Property**

(a) You acknowledge Your continuing obligations with regard to Confidential Information in accordance with Section 5(a) of the Employment Agreement. You affirm that You have complied with this provision, and You agree that You will continue to abide by the terms and conditions of Section 5(a) of the Employment Agreement.

(b) In accordance with Section 5(a)(iv) of the Employment Agreement, You agree that You shall, no later than the Separation Date, return all originals and copies in any form or medium (including memoranda, books, papers, plans, computer files, letters and other data) of all documents and records made or compiled by You and/or made available to You during the period of Your employment with the Company that contain confidential, proprietary, trade secret or other business information belonging to the Company and/or any of the Released Parties, whether printed, typed, handwritten, videotaped, transmitted or transcribed on data files or on any other type of media and whether or not labeled or identified as confidential, proprietary or trade secret. You further represent and warrant that You have not, and will not, directly or indirectly, at any time, now or ever in the future, download, print, copy, electronically transmit, disclose, release or retain any such information for personal use or any other purposes for Your own benefit or the benefit of any third party.

(c) In addition to having returned all originals and copies (in whatever format) of all Confidential Information and other business information belonging to the Company and the Released Parties, You warrant that You have returned all other written information regarding the Company and all Lantheus property and materials including, but not limited to, credit cards, calling cards, keys, keyfobs, identification badges, files, records, samples, computer disks, laptop computers, printers, personal digital assistants, and any other electronic equipment You were furnished by the Company; provided, that nothing in this Paragraph shall be construed to require You to return any documents that are in the public domain or any documents related to the terms of Your employment with the Company.

11. **Restrictive Covenant Agreements.**

You acknowledge and agree that You will be subject to and will abide by the terms and conditions of the restrictive covenant agreements in Section 5(c) of the Employment Agreement, including, among other covenants, the covenant against competition, the covenant against solicitation of employees, and the covenant against solicitation of clients and prospective clients. It is understood and acknowledged that the Restricted Period (as defined in the Employment Agreement) shall have commenced as of the Separation Date.

12. **No Tax Advice Provided.**

You agree that You have not been provided any advice by any of the Released Parties regarding the tax or withholding consequences of the payments and other benefits provided to You under this Agreement under any federal, state or local tax or withholding laws or regulations. You also agree that You will be solely responsible for the tax liabilities and consequences arising under any federal, state or withholding laws or regulations that may result from the payments made pursuant to Section 3(a)(i), Consulting Pay, or other payments or benefits referenced in this Agreement, and hold the Released Parties harmless from and indemnify them for any costs, fines, interest or penalties owed by You under such laws or regulations. Additionally, You agree that the Released Parties will not be required to pay any further sum to You, even if such tax or withholding consequences are not foreseeable at the time You sign this Agreement or are ultimately assessed in a manner which You do not anticipate at the time You sign this Agreement.

13. **Successors and Assigns.**

This Agreement shall not be assignable by You, but shall be binding upon You and upon Your heirs, administrators, representatives, executors, and successors. This Agreement shall be freely assignable by Lantheus without restriction and shall be deemed automatically assigned by the Company with Your consent in the event of any sale, merger, share exchange, consolidation or other business reorganization. This Agreement shall be binding upon, and shall inure to the benefit of, the Company's successors and assigns.

14. **Consultation with Counsel; Reasonable Time to Consider Agreement During Review Period; Voluntary Acceptance of this Agreement; Right and Time to Revoke; Effective Date.**

(a) You acknowledge that, through this writing, Lantheus has recommended that You consult with an attorney and tax advisor of Your own choosing before signing this Agreement, that sufficient time has been made available to You to consult with an attorney or tax advisor, and that You have, in fact, consulted Your attorney and tax advisor or knowingly waived the right to consult Your attorney and tax advisor.

(b) You understand that You have a period of twenty-one (21) days after Your receipt of this Agreement to review and consider the Agreement before signing it, except that if the last date of that period falls on a Saturday, Sunday or holiday observed by the Company, You will have until the close of business on the next immediate business day (the "Review Period"). You also understand that You may use as much of the Review Period as You wish before signing this Agreement. You agree that any material or immaterial changes to this Agreement will not restart the running of the Review Period.

(c) You may elect to accept this Agreement by sending a signed and dated original to Michael Duffy, the General Counsel of the Company, postmarked no later than the close of business on the last day of the Review Period, or by emailing to Mr. Duffy a true and complete PDF copy of a signed and dated Agreement no later than the close of business on the last day of the Review Period. To the extent that You sign this Agreement and return it to the Company prior to the expiration of the Review Period, You warrant that You have voluntarily and knowingly waived the remainder of the Review Period.

(d) By signing this Agreement, You warrant that You have carefully read and fully understand all of the terms of this Agreement, You are competent and of sound mind to execute this Agreement, and that You are knowingly and voluntarily signing this Agreement of Your own free will, act and deed. You further warrant that You have made such investigation of the facts pertaining to this Agreement and all matters contained herein as You deem necessary, desirable and appropriate, and agree that the Release provided for herein shall remain in all respects effective and enforceable and not subject to termination or rescission by reason of any later discovery of new, different or additional facts.

(e) You understand that, following Your execution of the Agreement, You will have a period of seven (7) calendar days to revoke Your acceptance of this Agreement by delivering written notification of any such revocation to Michael Duffy, the General Counsel of the Company, no later than the seventh (7th) calendar day after You sign it (the "Revocation Period"). Written notification of revocation may be delivered by facsimile transmission to Michael Duffy, the General Counsel of the Company, by first class U.S. mail sent to Michael Duffy, the General Counsel of the Company, or by hand-delivery or overnight mail to Michael Duffy, the General Counsel of the Company, provided that such written notification of revocation must be received by the Company no later than the close of business on the last day of the Revocation Period to be effective. If You timely revoke this Agreement during the Revocation Period, the Agreement will not be effective and enforceable and You will not receive the benefits and other payments described in Section 3 and its subparagraphs above.

(f) For purposes of this Agreement, the "Effective Date" as used throughout this Agreement shall mean the first (1st) calendar day after the Revocation Period expires, provided that a notice of revocation has not been timely served upon the Company by You prior to that date.

15. **Governing Law and Venue.**

This Agreement shall be subject to, and governed by, the laws of the State of New York applicable to contracts made and to be performed therein, without regard to conflict of law principles. With respect to any dispute arising out of or related to this Agreement, each Party hereby consents to the exclusive jurisdiction of the of the United States District Court for the District of Massachusetts or the Superior of the Commonwealth of Massachusetts, Middlesex County, and expressly agrees not to challenge venue or forum in the event of any litigation.

16. **Severability.**

Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such prohibition or invalidity and severed from this Agreement, without invalidating the remainder of such provision or remaining provisions of this Agreement.

17. **Proper Construction.**

(a) The language of this Agreement shall be construed within the context of the whole Agreement and according to its fair meaning, and not strictly for or against any of the Parties.

(b) The paragraph headings used in this Agreement are intended solely for convenience of reference and shall not in any manner amplify, limit, modify or otherwise be used in the interpretation of any of the provisions hereof.

18. **Amendments.**

This Agreement may be modified, altered or terminated only by an express written agreement between the Company and You, which agreement must be signed by both Parties or their duly authorized agents, and expressly reference and attach a copy of this Agreement to be effective.

19. **Counterparts.**

This Agreement may be executed in any number of counterparts and by different Parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

20. **Withholding.**

The Company shall be entitled to withhold from any amounts to be paid or benefits provided to You hereunder any federal, state, local or foreign withholding, FICA contributions or other taxes, charges or deductions which it is from time to time required to withhold.

21. **Code Section 409A.**

(a) The Parties agree that this Agreement shall be interpreted to comply with or be exempt from Section 409A of the Internal Revenue Code of 1986, as amended (including the regulations and guidance promulgated thereunder to the extent applicable, collectively, "Code Section 409A"), and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Code Section 409A. In no event whatsoever will the Company be liable for any additional tax, interest or penalties that may be imposed on You under Code Section 409A or any damages for failing to comply with Code Section 409A.

(b) A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits considered "nonqualified deferred compensation" under Code Section 409A upon or following a termination of employment unless such termination is also a "separation from service" within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a "termination," "termination of employment" or like terms shall mean "separation from service. With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Code Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits, to be provided in any other taxable year, provided, that, this clause (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Internal Revenue Code Section 105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii) such payments shall be made on or before the last day of Your taxable year following the taxable year in which the expense occurred. Whenever a payment under this Agreement specifies a

payment period with reference to a number of days (e.g., “payment shall be made within thirty (30) days following the date of termination”), the actual date of payment within the specified period shall be within the sole discretion of the Company.

22. **Entire Agreement.**

This Agreement constitutes the entire understanding of the Parties, supersedes all prior oral or written agreements (except as expressly stated in this Agreement) (including, but not limited to, the Employment Agreement), and cannot be modified except by an express writing signed by both Parties in accordance with Section 18 above. No agreements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by any Party, which are not set forth expressly in this Agreement. The Released Parties are express third party beneficiaries hereof. Notwithstanding the foregoing, this Agreement shall not be construed as altering, modifying, and supplanting or in any way changing or affecting the continued enforceability of Sections 4(g), 4(i), 5, 6, 13 and 18 of the Employment Agreement, which shall continue to survive and be in effect, except as otherwise expressly provided in this Agreement.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, intending to be forever legally bound hereby, the Parties have executed this Agreement.

Lantheus Medical Imaging, Inc.

By: /s/ Michael Duffy

Name: Michael Duffy

Title: Secretary

Accepted and Agreed:

/s/ Jeffrey Bailey

Jeffrey Bailey

Date: 8/27, 2015

[Retirement and Consulting Agreement]

AMENDMENT TO EMPLOYMENT AGREEMENT

This Amendment to Employment Agreement (this "Amendment") is entered into as of August 31, 2015, by and between Mary Anne Heino, an individual ("Employee"), and Lantheus Medical Imaging, Inc., a Delaware corporation (the "Company").

WHEREAS, the Company and the Employee are party to that certain Employment Agreement entered onto on August 12, 2013 (the "Initial Employment Agreement");

WHEREAS, the Initial Employment Agreement was amended and restated in its entirety by the parties pursuant to that certain amended and restated employment agreement, dated March 16, 2015 (as amended on June 25, 2015, the "Employment Agreement"); and

WHEREAS, capitalized terms that are not defined herein shall have the same meaning as set forth in the Employment Agreement.

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties agree as follows:

1. Amendments to Employment Agreement.

(a) Section 2.a. of the Employment Agreement is amended and restated in its entirety to read as follows:

"a. Executive shall serve as the Company's President and Chief Executive Officer and as a member of the Board of Directors of Lantheus Holdings, Inc. (the "Board"). In such capacities, Executive shall report to the Board, and Executive shall have such duties and responsibilities as are consistent with such titles and positions and/or such other duties and responsibilities as may be assigned from time to time by the Board. If requested, Executive shall serve as an officer or a member of the Board of Directors of any of the Company's subsidiaries or affiliates without additional compensation."

(b) The first sentence of Section 3 of the Employment Agreement is amended and restated in its entirety to read as follows:

"During Executive's employment hereunder, the Company shall pay Executive a base salary at the annualized rate of \$600,000, payable in regular installments in accordance with the Company's payment practices from time to time."

(c) The first sentence of Section 4 of the Employment Agreement is amended and restated in its entirety to read as follows:

With respect to each full fiscal year ending during Executive's employment hereunder, Executive shall be eligible to earn an annual bonus award of eighty percent (80%) of Executive's Base Salary (the "**Target**") based upon achievement of annual EBITDA and/or other performance targets established by the Compensation Committee of the Board within the first three months of each fiscal year (the "**Annual Bonus**").

2. Award of Restricted Stock. In connection with the execution of this Amendment, and in any event within five (5) days after the date hereof, Executive shall be granted 227,000 shares of restricted common stock (the "RSAs") of Lantheus Holdings, Inc. pursuant to the Lantheus Holdings, Inc. 2015 Equity Incentive Plan. The RSAs shall vest in equal annual installments over a period of four years, with such other terms and provisions as are set forth in the Restricted Stock Award Agreement memorializing such grant.

3. References. All references in the Employment Agreement to "this Agreement" and any other references of similar import shall hereinafter refer to the Employment Agreement as amended by this Amendment.

4. Remaining Provisions. Except as expressly modified by this Amendment, the Employment Agreement shall remain in full force and effect. This Amendment embodies the entire agreement and understanding of the parties hereto with respect to the subject matter hereof, and supersedes all prior and contemporaneous agreements and understandings, oral or written, relative thereto.

5. Governing Law. This Amendment shall be governed by, construed and interpreted in all respects, in accordance with the laws of the State of New York, without regard to conflicts of laws principles thereof.

6. Counterparts. This Amendment may be executed by either of the parties hereto in counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument.

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first set forth above.

LANTHEUS MEDICAL IMAGING, INC.

By: /s/ Michael Duffy

Name: Michael Duffy

Title: Secretary

ACCEPTED AND AGREED:

/s/ Mary Anne Heino

Name: Mary Anne Heino

Date: August 31, 2015

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Mary Anne Heino, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Lantheus Holdings, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 4, 2015

/s/ MARY ANNE HEINO
Name: Mary Anne Heino
Title: *President and Chief Executive Officer*

**CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, John Bakewell, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Lantheus Holdings, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: November 4, 2015

/s/ JOHN Bakewell
Name: John Bakewell
Title: *Chief Financial Officer*

**CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Each of the undersigned hereby certifies that to his knowledge the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015 of Lantheus Holdings, Inc. (the "Company") filed with the Securities and Exchange Commission on the date hereof fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 4, 2015

/s/ MARY ANNE HEINO
Name: Mary Anne Heino
Title: *President and Chief Executive Officer*

Dated: November 4, 2015

/s/ JOHN Bakewell
Name: John Bakewell
Title: *Chief Financial Officer*

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

